

ACKNOWLEDGEMENT TO SPONSORS

The ISODP 2015 would like to acknowledge the following companies for their generous contribution.

PLATINUM LEVEL



GOLD LEVEL



SILVER LEVEL









KOREA GOVERNMENT SPONSORS







TABLE OF CONTENTS

welcome Letter from Korea	•••••	2
Welcome Letter from ISODP President		3
Committees		4
Information about Societies		
About ISODP		5–6
About TTS		6
About KST		6
About KODA		6
TTS and ISODP Scientfic Awards		7
Congress Information		8–9
Congress Venue		10–11
Program-at-a-Glance		12-13
Abstract Reviewers		14
Invited Speakers		15
Session Moderators		16
Detailed Program		
Saturday, October 17, 2015		17
Sunday, October 18, 2015		19–28
Monday, October 19, 2015		29–39
Tuesday, October 20, 2015		41–49
World Day of Organ Donation and Transplantation		51
Social Activites		52-53
Exhibit Information		
Exhibitor Hours and List of Exhibitors		54
Exhibit Floor Plans		55
Sponsor Descriptions		56-59
Exhibitor Descriptions		60–65
Discover Seoul		66
Hotel and City Map		67
Transportation		68-69
Sponsor Advertisements		70-78
Presenter Index		79–81

WELCOME LETTER FROM KOREA

Distinguished Members and Guests,

On behalf of the Organizing Committee and the Korean Society for Transplantation, it gives us great pleasure to welcome all of you to the 13th Congress of the International Society for Organ Donation and Procurement to be held at the Conrad Hotel, Seoul, Korea, from October 17th to 20th, 2015.

In the tradition of past congresses, a splendid variety of organized sessions with oral and poster presentations will be led by internationally recognized experts from the field of organ and tissue donation and procurement. Festive social events, including the welcome reception and congress dinner, will offer great opportunities to build new friendships as well as catch up with old friends and colleagues.

For the 13th Congress, we have planned a stimulating scientific program consisting of a keynote lecture along with 4 plenary sessions, 4 early morning symposia, 11 concurrent symposia, 2 round-table discussions with a debate session, as well as oral and poster presentations. Replete with brilliant talks on the latest issues and recent research in the field, we have prepared an intellectually demanding and engaging experience for all participants. Most importantly, this meeting aims at developing organ donation systems in Asian countries which are in critical phases of increasing their transplantation activity.

We would like to thank our sponsors for their generous support of ISODP2015. We would also like to convey our sincere gratitude to the Local Organizing Committee and Scientific Program Committee as well as the Advisory Committee for their invaluable contributions. This congress would not have been possible without them.

We hope you all enjoy the beautiful weather of Korea as well as the delicious food, culture and entertaining sites around the dynamic city of Seoul. We anticipate a fruitful meeting in which you will benefit from the rich scientific programs, have the chance to strengthen your professional networks, and leave with unforgettable memories.

With best wishes,

Ha Jongwon, MD, PhD Congress Chair ISODP2015

Lee Suk-Koo, MD, PhDChairman of the Board
Korean Society for Transplantation

Sullent

WELCOME LETTER FROM ISODP PRESIDENT

Dear Colleagues,

On behalf of the Council of the ISODP, I am happy to welcome you to the International Society for Donation and Procurement (ISODP) 2015 Biennial Congress. The Congress Scientific Program Committee, led by Drs. Ha and Kirste, have assembled an exceptional scientific program addressing topics of interest to all disciplines in the field of organ and tissue donation and transplantation. As evidenced by the program and invited speakers, I think you will agree, they have been very successful. The program focuses on real and current issues we are facing today. Here meaningful ideas and innovation will be presented and debated through presentation, panels and discussion. It is my hope that you will leave Korea invigorated and that our passionate discussions will inspire and help us to seed change, worldwide.

As well as attending the outstanding sessions, I encourage you to participate in as many other conference related activities as possible. In particular, we draw your attention to three events that will be significantly more productive with membership participation:

- October 17 at 10:30, The World Day of Organ Donation and Transplantation Join us for this international celebration in Yeoeui-do Park;
- October 19 at 18:00, ISODP General Assembly
 Here we will chart the course for the coming years in an effort to advance the Society;
- October 19 at 19:30, The ISODP Social Evening:
 A time for you to experience Korean culture at its finest.

In closing, we are excited about the excellent opportunity for local and international delegates to interact with a wide range of experts in the transplantation field. We hope that you have a wonderful time and that you are able to strengthen your personal and professional networks – enjoy the meeting.

Sincerely,

Kimberly Young

Kimberly P. Young, BScN President of ISODP

Director, Donation and Transplantation, Canadian Blood Services

COMMITTEES

ISODP PRESIDENT

Kimberly P. Young, Canada

CONGRESS CHAIR

Ha Jongwon, Korea

CONGRESS SECRETARY

Min Sang-II, Korea

CONGRESS EXECUTIVE COMMITTEE

Ha Jongwon, Korea Lee Suk Koo, Korea Faissal Shaheen, Saudi Arabia Kimberly P. Young, Canada

SCIENTIFIC **C**OMMITTEE **C**HAIR

Günter Kirste, Germany

LOCAL ORGANIZING COMMITTEE

Hwang Shin Jang Kyung Sook Kang Hyunjin Kim Bok Nyeo Kim Dong-Chan Kim Dong-Sik

Kim Myoung Soo

Kim Soon-II Kim Sungjoo

Kwon Choon Hyuck David

Yi Nam-Joon

Yun Ik Jin

LOC ADVISORY COMMITTEE

Ahn Curie Cho Won-Hyun Chung Sang Young

INFORMATION ABOUT THE SOCIETIES

The mission of the International Society for Organ Donation and Procurement (ISODP) is to foster, promote and develop all aspects of organ and tissue donation and procurement. The ultimate aim is to increase the supply of high quality organs and tissue to match the need.



The mission of the ISODP can be accomplished by focusing on:

- Societal attitudes and legislative requirements
- Perfecting the process of donation and procurement
- · Ways of expanding the donor pool
- Measures to minimize donor organ injury
- The development and facilitation of educational programs
- · Ethical matters related to organ and tissue donation and procurement

For more information, visit www.isodp.org

2013-2015 COUNCIL MEMBERS

President: Kimberly P. Young, Canada President-Elect: Marti Manyalich, Spain S.A. Anwar Naqvi, Pakistan **Past President: Secretary:** Günter Kirste, Germany **Treasurer:** Howard M. Nathan, USA **Councilors:**

Louis Beaulieu, Canada Helen Opdam, Australia Stephen Beed, Canada Faissal A.M. Shaheen, Saudi Arabia

> Jeremy R. Chapman, Australia Martin Alejandro Torres, Argentina Susan Gunderson, United States Haibo Wang, People's Republic of China

> > Email: sections@tts.org

Jongwon Ha, Korea

CONTACT INFORMATION

International Society for Organ Donation and Procurement

(a Section of The Transplantation Society) Tel: +1.514.874.1717 505 boul, René-Lévesque Ouest, Suite 1401 Fax: +1.514.874.1716 Montreal, OC H2Z 1Y7

Canada Website: www.isodp.org

INFORMATION ABOUT THE SOCIETIES

ISODP GENERAL ASSEMBLY

ISODP Members are invited to attend the ISODP General Assembly, which will be held on Monday, October 19th from 18:00 to 19:00; wine and snacks will be served for those attending the meeting. During this meeting the membership will receive an update on the Society's activities and the Scientific Awards will be presented.

INFORMATION ON TTS

The Transplantation Society is an international forum for the world-wide advancement of organ transplantation.



The Transplantation Society will provide the focus for global leadership in transplantation:

- Development of the science and clinical practice
- · Scientific communication

For more information, visit www.tts.org

- · Continuing education
- Guidance on the ethical practice





Information on KST

The Korean Society for Transplantation (KST) was established in 1969 and currently more than 1,000 members are registered. Clinical and basic research in all fields of transplantation are actively performed. KST endorsed the Declaration of Istanbul and aims at national self-sufficiency while upholding ethical and transparent organ donation and transplantation

Information on KODA

management and family care.

The Korea Organ Donation Agency (KODA) is the national organ procurement organization of Korea which was established in 2011 in accordance with the new Transplant Act. KODA is non-for-profit organization and fully supported by the Ministry of Health and Welfare. KODA is focusing high standard donor

TTS AND ISODP SCIENTIFIC AWARDS

The Transplantation Society and the International Society for Organ Donation and Procurement are pleased to announce the recipients of the 2015 ISODP Scientific Awards. The awards will be presented in conjunction with the ISODP General Assembly on **Monday, October 19th, 18:00 to 19:00.**

Look for the



in the program, which identifies the award winners.

Manish Balwani, India

661 - ATTITUDE AND AWARENESS TOWARDS ORGAN DONATION IN WESTERN INDIA

Luiz Gustavo Dias da Curz, Brazil

490 - MANAGEMENT TOOLS OF A COMMISSION-HOSPITAL DONATION OF ORGANS AND TISSUES: PROFILE OF THE NURSING TEAM.

Won Jung Lee, Korea

366 - ASSESSMENT OF POTENTIAL ORGAN DONATION IN SINGLE INSTITUTE

Alvin Li, Canada

635 - REGISTRATION FOR DECEASED ORGAN AND TISSUE DONATION AMONGST NEW CANADIANS: A POPULATION - BASED STUDY

Mayuko Ogawa, Japan

571 - REGIONAL SURVEY OF TISSUE DONATION IN PUBLICS AND MEDICAL STAFFS AROUND OSAKA

Shaifali Sandal, Canada

621 - RENAL RESISTANCE MEASURED DURING PULSATILE PERFUSION AND LONG-TERM KIDNEY TRANSPLANT OUTCOMES

Rodrigo Sarlo, Brazil

633 - IMPACT OF INTRODUCING FULL-TIME, IN-HOUSE COORDINATORS ON REFERRAL AND ORGAN DONATION RATES IN RIO DE JANEIRO PUBLIC HOSPITALS:

A HEALTHCAREINNOVATION PRACTICE

Thomas Schachtner, Germany

618 - THE IMPACT OF CHRONIC PAIN, HYPERTENSION AND FATIGUE ON LONG-TERM QUALITY OF LIFE AFTER LIVING KIDNEY DONATION

Joyce Trompeta, United States

682 - FACTORS THAT ARE ASSOCIATED WITH POTENTIAL LIVING DONORS WHO DO NOT COMPLETE THE EVALUATION PROCESS

Mikiko Yoshikawa, Japan

491 - TRANSPLANT PROCUREMENT MANAGEMENT (TPM) MODEL TRAINING; DRAMATIC REFORM OF THE MINDSET OF HEALTH CARE PROFESSIONALS IN HYOGO PREFECTURE, JAPAN

CONGRESS INFORMATION

PRESENTER GUIDELINES

All speakers have to check into the Speaker Preview Room at least 3 hours in advance of their session to download their presentation onto the central computer.

The Speaker Preview Room is located in **Studio 8** on the 6th floor and will be open during the following hours:

Saturday, October 17 08:00 to 18:00
Sunday, October 18 06:30 to 18:00
Monday, October 19 06:30 to 18:00
Tuesday, October 20 08:00 to 18:00

POSTER SESSIONS

The Posters Sessions 1 to 3 will be held in the **Park Ballroom Foyer** on October 18th from 18:00-19:00.

The Posters Sessions 4 to 6 will be held in the **Park Ballroom Foyer** on October 19th from 18:00-19:00.

Mount Date and Time for Presenters:

Poster sessions 1 to 3: Sunday, October 18, 2015 from 07:00 to 09:30 Poster sessions 4 to 6: Monday, October 19, 2015 from 07:00 to 09:30

Dismount Date and Time for Presenters:

Poster sessions 1 to 3: Sunday, October 18, 2015 as of 19:00 Poster sessions 4 to 6: Monday, October 19, 2015 as of 19:00

REGISTRATION HOURS

Registration is located in the lobby of the 3rd floor and will be open during the following hours:

• Saturday, October 17 08:00 to 12:30 and 15:30-19:00

Sunday, October 18 06:30 to 18:00
 Monday, October 19 07:00 to 18:00
 Tuesday, October 20 08:00 to 18:00

CONGRESS INFORMATION

NAME BADGES

For security and regulation purposes, please wear your badge during all congress sessions and social events.

INTERNET WIFI INFORMATION

Free Wi-fi is available on the 5th floor of the Conrad Hotel from October 18th to October 20th. The log-in information will be announced on-site.

ABSTRACTS AND TRANSPLANTATION JOURNAL

Please note that all abstracts are available online only and can be viewed on the congress website at **www.isodp2015.org**.

You can use either our mobile program to view the session program, which includes a copy of the abstracts, or you can access the *Transplantation Journal* to view the complete abstract book.

WEB RECORDINGS

All registered attendees will have the chance to view the congress session recordings through the Congress website for up to a year after the congress.

CONGRESS VENUE

The congress is held at the Conrad Seoul, occupying one of the four towers of the renowned International Finance Centre (IFC). It is located at 23-1 Yeouido-dong Yeongdeungpo-gu, in Seoul. Tel: 82-2-6137-7000

Registration Area Lobby – Level 3F
 Speaker Preview Room Studio VIII – Level 6F
 Plenary Room Grand Ballroom - Level 3F

Symposia/Orals Rooms Grand Ballroom I, II and III - Level 3F

Studio I-II - Level 6F


Workshops Studio I-II – Level 6F

Exhibit, Poster
 Park Ballroom and Foyer Area – Level 5F

Lunch Grand Ballroom – Level 3F
 Breaks Foyer Area – Level 3F, 5F


Welcome Reception
 Park Ballroom and Foyer Area – Level 5F

Congress Dinner
 Closing Ceremony
 Grand Ballroom - Level 3F
 Grand Ballroom - Level 3F



CONGRESS VENUE

5F



6F



PROGRAM-AT-A-GLANCE: DAY 1 AND 2

	DAY 1 - SATURDAY, OCTOBER 17 th				DAY 2	- SUI	NDAY, OCTOBI	ER 18 th		
					Grand Ballroom I	Grand Ballrooi		Grand Ballroom III	Studio I-II	
07:30						Morning S Public a	ympo		Early Morning Symposium:	
08:00					Pro	fessional I		tion	Donor Management	
08:30				1						
09:00						Plenary S		:		
09:30	Pre-Congress Workshop:	Pre-Congress Workshop:	Pre-Congress Workshop:			Etili	G			
10:00	Safety in	Is Pumping Better for	Tissue Donation							
10:30	Organ and Tissue Donation				Coff	ee Break (Park I	Ballroom Foyer <i>F</i>	Area)	
11:00	(Studio I)	(Studio II)	(Studio III)		Concurrent Symposium:	Concurr Symposi	ium:	Concurrent Symposium:	Oral Presentation:	
11:30				World Day of Organ	Vascularized Composite	Preserva and Perfu		Donor Derived or Transmitted	Bioethics & Law	Exhi
12:00				Donation and	Allograft			Disease		bition/
12:30	Transplantation (Yeouido Park)				Lunch Break (Level 3F)			Poster		
13:00										Exhibition / Poster Viewing(Level 5F)
13:30						Plenary Se				ıg (Lev
14:00					Donation	after Circ	ulato	ry Death		el SF)
15:00					Coff	ee Break (Park I	Ballroom Foyer <i>F</i>	(rea)	
15:30					Oral	Oral		0ral	Oral	
16:00	Would		m of	-6-6:	Presentation: Family Care	Presenta Transmis of Dise	ssion	Presentation: Tissue Donation	Presentation: Determination of Brain Death	
16:30	world	Day of Organ Dona (Conrad Hotel	- Studio I-II-III)	паноп	Concurrent	Concurr		Concurrent	Oral	
17:00					Symposium: Future of	Symposi Orgai	ium: n	Symposium: Quality	Presentation: Donation after	
17:30					Donation	Allocati Polic		Improvement	Circulatory Death	
18:00					Poster Sess Allocatio			oster Session: ensive Care and	Poster Ses Living Dor	
18:30					Quality Manag	gement		or Management		
19:00			eremony &							
19:30			Reception							
20:00			oom I-II-III & n Foyer Area)							
20:30										

PROGRAM-AT-A-GLANCE: DAY 3 AND 4

	DAY 3 - MONDAY, OCTOBER 19 th					DAY 4 - TUE	SDAY, OCTOB	ER 20 th		
	Grand Ballroom I	Grand Ballroom II	Grand Ballroom III	Studio I-II		Grand Ballroom I	Grand Ballroom II	Grand Ballroom III	Studio I-II	
07:30 08:00	Early	Morning Sympo Family Care	sium:	Early Morning Symposium: Crisis Manage- ment of Donor						•
08:30				ment of Bollot						
09:30		Plenary Session Tissue Donation					Plenary Session: Living Donation			
10:00										
10:30		T	Ballroom Foyer A					Ballroom Foyer <i>l</i>		
11:00	Oral Presentation: Quality and Data	Oral Presentation: Improving Knowledge	Oral Presentation: Best Practices in Donation	Oral Presentation: Quality Management		Oral Presentation: Organisation of Organ	Oral Presentation: Organ Preservation	Oral Presentation: Public Policy	Oral Presentation: Late-Breaking Abstracts	
12:00	Management	Kilowieuge	III Dollation	Management	Exhibition / Poster Viewing (Level 5F	Donation	rreservation		Austracts	Exhibition / Poster Viewing (Level 5F)
12:30			Break		on / Post		Lunch Brea	k (Level 3F)		on / Post
13:00	(Level 3F)				er View		: Controversies i			ter View
13:30	Plenary: Keynote Lecture				ing (Le	Trans	plantation from	1 DCD		ing (Le
14:00	Coff	ee Break (Park I	Ballroom Foyer A	rea)	vel 5F	Coffe	ee Break (Park I	Ballroom Foyer <i>l</i>	lrea)	vel 5F
14:30 15:00	Oral Presentation: Intensive Care	Oral Presentation: Education in	Oral Presentation: Allocation	Oral Presentation: Donation after	J	Oral Presentation: Public	Oral Presentation: Donor	Oral Presentation: Living	Round Table Discussion: Perspectives from)
15:30		Organ Donation		Brain Death		Campaigns	Management	Donation	Bangladesh, Malaysia Mongolia, Myanmar, Pakistan and Vietnam	
16:00	Coff	ee Break (Park I	Ballroom Foyer A	Area)		Coffe	ee Break (Park I	Ballroom Foyer <i>l</i>		
16:30	Concurrent Symposium:	Concurrent Symposium:		Round Table Discussion:		Concurrent Symposium:	Concurrent Symposium:	Concurrent Symposium:		
17:00	Paired Donation	Mass Media		Perspectives from Japan, Taiwan,		Challenging Aspects	Promoting Organ Donation	Tissue Donation		
17:30				Thailand, Hong Kong, India, China		in the Work of a Coordinator	Donation			
18:00	Poster Session: Education and	Poster Session: Determination	Poster Session: Tissue Donation	ISODP Business Mooting			Closing Ceremon	ıy		
18:30	Communication of Brain Death Meeting & Awards									
19:00										
19:30										
20:00			s Dinner room I-II-II)							
20:30										

ABSTRACT REVIEWERS

Mario M. Abbud-Filho, Brazil Louis Beaulieu. Canada Michael A. Bos, The Netherlands Scott A. Brubaker, United States Jeremy R. Chapman, Australia Tina A. Coco, Australia Valter Duro Garcia, Brazil John S. Gill. Canada Susan Gunderson, United States Jongwon Ha, Korea Philippe Hantson, Belgium Richard Hasz, United States George A. Herrera, United States Michael G. Ison, United States Soon-Il Kim, Korea Sungjoo Kim, Korea **Günter Kirste**, Germany Dominique E. Martin, Australia Sang-Il Min, Korea Thomas D. Mone, United States S.A. Anwar Nagvi, Pakistan Howard M. Nathan, United States Kevin O'Connor, United States Helen I. Opdam, Australia Dariusz J. Patrzalek, Poland Timothy L. Pruett, United States Stefan Schneeberger, Austria Faissal A.M. Shaheen, Saudi Arabia Kazunari Tanabe, Japan Stefan G. Tullius, United States Kimberly P. Young, Canada

INVITED SPEAKERS

Louis Beaulieu, Canada Stephen Beed, Canada Adam W. Bingaman, United States Michael A. Bos. The Netherlands **Gerald Brandacher**, United States **Kerstin Brehm**, Germany Scott A. Brubaker, United States **David N. Campbell**, United States Serghei Cebotari, Germany Jeremy R. Chapman, Australia Won-Hyun Cho, Korea John P. Clarke, United States Tina A. Coco. Australia Francis L. Delmonico. United States Visist Dhitavat, Thailand Thi Ngoc Thu Du, Vietnam Norihide Fukushima, Japan John S. Gill, Canada Chad Gordon, United States Susan Gunderson, United States Jongwon Ha, Korea Philippe Hantson, Belgium George A. Herrera, United States Marisa R. Herson, Australia **Kent Holloway**, United States James A. Hynds, United States Michael G. Ison, United States Myoung Soo Kim, Korea Sang Il Kim, Korea Soon-Il Kim, Korea **Günter Kirste**, Germany **Jenny Koo**, Hong Kong Susan Mau Larson, United States Po-Chang Lee, Taiwan Suk-Koo Lee, Korea Alan B. Leichtman, United States Li Li, People's Republic of China Peter S. MacDonald, Australia

Fadhilah Zowyah Lela Yasmin Mansor, Malaysia

Marti Manyalich, Spain Dominique E. Martin, Australia Kerstin Moench, Germany **Thomas D. Mone**, United States Philippe Morel, Switzerland Paul Murphy, United Kingdom Sungwon Na, Korea **Thomas Nakagawa**, United States S.A. Anwar Nagyi, Pakistan **Howard M. Nathan**, United States **Dimitri Novitzky**, United States **Kevin O'Connor**, United States Joo Youn Oh. Korea Helen I. Opdam, Australia Chung-Gyu Park, Korea Dariusz J. Patrzalek. Poland Jacques Pirenne, Belgium Timothy L. Pruett, United States Mir M. Rahman, Bangladesh Meg M. Rogers, United States **Alvaro Rojas-Pena**, United States John D. Scandling, United States Stefan Schneeberger, Austria Dorry L. Segev, United States Faissal A.M. Shaheen, Saudi Arabia Naoshi Shinozaki, Japan Sunil Shroff, India Maria Siemionow, United States Andre Simon, United Kingdom Mark D. Stegall, United States Htar Kyi Swe, Myanmar Kazunari Tanabe, Japan **Allison Tong**, Australia Stefan G. Tullius, United States James J. Yoo, United States Kimberly P. Young, Canada Dirk K.V. Ysebaert, Belgium

Session Moderators

Curie Ahn, Korea Louis Beaulieu. Canada Stephen Beed, Canada Adam W. Bingaman, United States Michael A. Bos, The Netherlands Jeremy R. Chapman, Australia Hong Rae Cho, Korea Won-Hyun Cho, Korea Sang Young Chung, Korea Tina A. Coco, Australia Theresa A. Daly, United States Francis L. Delmonico, United States Susan Gunderson, United States Jongwon Ha. Korea Richard Hasz, United States Shin Hwang, Korea Michael G. Ison, United States Jae-Won Joh, Korea Hyunjin Kang, Korea Bok Nyeo Kim, Korea Dong Goo Kim, Korea Dong-Chan Kim, Korea Dong-Sik Kim, Korea Hyoung Tae Kim, Korea Joong-Kyung Kim, Korea Myoung Soo Kim, Korea Sang Il Kim, Korea Soon-Il Kim, Korea Sungioo Kim, Korea Yeong Hoon Kim, Korea Young Hoon Kim, Korea **Günter Kirste**, Germany Choon Hyuck David Kwon, Korea Ivo Kwon, Korea Oh Jung Kwon, Korea Sung-Tack Kwon, Korea

Suk-Koo Lee, Korea Young Joo Lee. Korea Alan B. Leichtman, United States Marti Manyalich, Spain Dominique E. Martin, Australia Sang-Il Min, Korea Kerstin Moench, Germany Thomas D. Mone. United States In-Sung Moon, Korea Philippe Morel, Switzerland Paul Murphy, United Kingdom Sungwon Na, Korea **Thomas Nakagawa**, United States S.A. Anwar Nagvi, Pakistan Howard M. Nathan, United States Kevin O'Connor, United States Chang Kwon Oh, Korea Helen I. Opdam, Australia Hyo-Chae Paik, Korea Jae Berm Park, Korea Su-Kil Park, Korea Dariusz J. Patrzalek, Poland Faissal A.M. Shaheen, Saudi Arabia Maria Siemionow, United States Andre Simon, United Kingdom Kyung-Suk Suh, Korea Stefan G. Tullius, United States Haibo Wang, Hong Kong Chul Woo Yang, Korea Nam-Joon Yi, Korea Kimberly P. Young, Canada Dirk K.V. Ysebaert, Belgium Hee Chul Yu, Korea Ik Jin Yun, Korea

Jae Myeong Lee, Korea

09:00-12:00	Pre-Congress Workshop: Safety in Organ and Tissue Donation	Studio I
100	GENERAL ASPECTS Michael G. Ison, United States	
101	VIROLOGY TESTING Sang Il Kim, Korea	
102	TESTING FOR MALIGNANT DISEASE Günter Kirste , Germany	
09:00-12:00	Pre-Congress Workshop: Is Pumping Better for Organ Donation?	Studio II
110	ORGAN AND TISSUE PRESERVATION: PATHOPHYSIOLOGY, CONSEQUENCES AND NOVEL CONCEPTS Stefan G. Tullius, United States	
111	HEART PRESERVATION WITH PUMPING SYSTEM - RESULTS OF THE EUROPEAN TRIALS Kerstin Brehm, Germany	
112	LUNG PRESERVATION WITH PUMPING SYSTEM - A NEW APPROACH Andre Simon , United Kingdom	
09:00-12:00	Pre-Congress Workshop: Tissue Donation	Studio III
120	HOW TO IMPROVE TISSUE DONATION? Howard M. Nathan, United States	
121	CORNEA DONATION Joo Youn Oh, Korea	
122	STORAGE OF TISSUES AND SAFETY ASPECTS George A. Herrera, United States y	
123	SAFETY AND TRACEABILITY OF TISSUES AND ORGAN Scott A. Brubaker, United States	
18:30–19:30	Plenary: Opening Ceremony	Grand Ballroom I-II-III
	WELCOME ADDRESS Jongwon Ha, Korea	
	OPENING ADDRESS Kimberly P. Young, Canada	
	CONGRATULATORY ADDRESS Jin Yeop Jung, Minister of the Ministry of Health and Welfare, Korea	
	CONGRATULATORY ADDRESS Suk-Koo Lee, Korea	
	CONGRATULATORY ADDRESS Francis L. Delmonico, United States	
	WELCOME PERFORMANCES	
19:30-21:00	Welcome Reception	Park Ballroom Foyer Area

Notes

07:30-08:30	Early Morning Symposium: Public and Professional Education	Grand Ballroom I-II-III
	Chairs: Soon-Il Kim, Korea and Marti Manyalich, Spain	
200	PUBLIC AWARENESS IMPROVEMENT Won-Hyun Cho, Korea	
201	EDUCATION - PROFESSIONALS Susan Gunderson, United States	
202	EDUCATION FOR THE PUBLIC AT ALL AGES Kimberly P. Young, Canada	
07:30-08:30	Early Morning Symposium: Donor Management	Studio I-II
	Chairs: Stephen Beed, Canada and Young Joo Lee, Korea	
210	DONOR QUALITY ASSESSMENT Louis Beaulieu, Canada	
211	DONOR MANAGEMENT AND ORGAN RESUSCITATION Thomas Nakagawa , United States	
212	RECOVERY SURGERY Dariusz J. Patrzalek , Poland	'
08:30-10:30	Plenary: Ethics	Grand Ballroom
	Chairs: Günter Kirste, Germany and Curie Ahn, Korea	
220	INCENTIVES FOR ORGAN DONATION Michael A. Bos, Netherlands	
221	DICG UPDATE: PROGRESS AND CHALLENGES Jeremy R. Chapman, Australia	
222	PAEDIATRIC PROTECTIONISM: IS ETHICAL ANXIETY UNDERMINING DECEADominique E. Martin, Australia	ASED DONATION?
223	ORGAN DONATION AFTER PATIENT'S REQUEST FOR PHYSICIAN AIDED EU Dirk K.V. Ysebaert , Belgium	THANASIA
10:30-11:00	Coffee Break	Park Ballroom

11:00–12:30	Concurrent Symposium 1: Vascularized Composite Allograft	Grand Ballroom I
	Chairs: Faissal A.M. Shaheen, Saudi Arabia and Sung-Tack Kwon, Korea	
230	HOW TO APPROACH POTENTIAL VCA DONOR FAMILY Maria Siemionow, United States	
231	DONOR MATCHING AND RECOVERY PROCESS Gerald Brandacher, United States	
232	EXPERIENCE OF EXTREMITY TRANSPLANTATION Stefan Schneeberger, Austria	
233	EXPERIENCE OF FACE TRANSPLANTATION Chad Gordon, United States	
11:00-12:30	Concurrent Symposium 2: Preservation and Perfusion	Grand Ballroom II
	Chair: Dirk K.V. Ysebaert, Belgium and Choon Hyuck Kwon, Korea	
240	KIDNEY Jacques Pirenne, Belgium	
241	PRESERVATION OF LIVERS FOR TRANSPLANTATION Stefan G. Tullius , United States	
242	HEART Andre Simon, United Kingdom	
243	LUNG Andre Simon , United Kingdom	
11:00-12:30	Concurrent Symposium 3: Donor Derived or Transmitted Disease	Grand Ballroom III
	Chairs: Sang Il Kim, Korea and Kimberly P. Young, Canada	
250	DONOR DERIVED INFECTION, BACTERIAL Michael G. Ison, United States	
251	DONOR TRANSMITTED MALIGNANCIES Kerstin Moench , Germany	
252	DONOR DERIVED INFECTIONS, VIRAL Sang II Kim, Korea	
253	POISONED DONOR / NEUROLOGICAL DISEASES / INHERITED DISEASE	

11:00-12:30	Oral Presentation: Bioethics & Law	Studio I-II
	Chairs: Jeremy R. Chapman, Australia and Ivo Kwon, Korea	
259	MISSED OPPORTUNITIES AFTER CARDIAC DEATH ORGAN DONORS: SHOULD EVERY REFERRAL BE PURSUED? A LARGE SINGLE US ORGAN PROCUREMENT ORGANIZATION EXPERIENCE Steven M. Rudich, United States	
260	ARE FINANCIAL INCENTIVES FOR LIVING KIDNEY DONATION REALLY A MORAL IMPERATIVE? Dominique E. Martin , Australia	
261	KIDNEY RECIPIENTS SOURCING AND RECRUITING THEIR OWN COMMERCIAL KIDNEY DONORS PRIOR TO ACCOMPANYING THEM TO OVERSEAS CENTERS FOR TRANSPLANTATION. SIX CASE STUDIES OF AN EMERGING MODEL OF ORGAN TRAFFICKING INVOLVING ONLINE MEDICAL TOURISM BROKERS Campbell Fraser, Australia	
262	RECONFIGURING THE DECEASED DONOR PROGRAM IN INDIA Preeti Gupta, India	
263	ORGAN DONATION AFTER EUTHANASIA IN THE NETHERLANDS Jan Bollen, The Netherlands	
265	A STUDY OF THE PUBLIC OPINION ON THE MEDICAL, LEGAL, ETHICAL AND SOCIAL ASPECTS OF TRANSPLANTATION Marek Ostrowski, Poland	
266	RELATIONSHIPS BETWEEN SOCIAL ATTITUDES TOWARDS DECEASED ORGAN DONATION AND THE DONATION RATES IN POLAND – THE COUNTRY WITH OPTING-OUT SYSTEM Jarosław Czerwiński, Poland	
267	INTERNATIONAL SYSTEMS AND MECHANISMS FOR ASSESSING TRACEABILIT AND TRANSPARENCY OF ORGAN DONATIONS David Matas , Canada	Υ
268	LEGAL ISSUES CONCERNING EYE DONATION IN BANGLADESH Mir M. Rahman , Bangladesh	
12:30-13:30	Lunch Break	Level 3F

13:30-15:00	Plenary: Donation after Circulatory Death	Grand Ballroom
	Chairs: Suk-Koo Lee, Korea and Howard M. Nathan, United States	
270	DETECTION OF DCD Alvaro Rojas-Pena, United States	
271	HOSPITAL PROTOCOLS FOR CONTROLLED DCD Paul Murphy , United Kingdom	
272	HOSPITAL PROTOCOLS FOR UNCONTROLLED DCD Marti Manyalich, Spain	
15:00-15:30	Coffee Break	Park Ballroom Foyer Area
15:30-16:30	Oral Presentation: Determination of Brain Death	Studio I-II
	Chairs: Stefan G. Tullius, United States and Hyo-Chae Paik, Korea	
280	A STUDY ON THE BRAIN DEATH DETERMINATION PROCEDURE IN KOREA: FOCUSING ON EEG Ohhyuk Yun, Korea	
281	SPONTANEOUS AND REFLEX MOVEMENTS OF THE BRAIN DEATH IN YOUNGNAM REGION OF KOREA Minhwa Kim , Korea	
282	EVALUATION OF COMPUTED TOMOGRAPHIC ANGIOGRAPHY WITH LOW VOLUME OF CONTRAST FOR THE CONFIRMATION OF CEREBRAL CIRCULATORY ARREST IN BRAIN DEATH DIAGNOSIS. Romuald Bohatyrewicz, Poland	
283	PULMONARY MICROCIRCULATION INTRAVITAL MICROSCOPIC STUDY: THE IMPACT OF BRAIN DEATH INDUCTION IN RATS Isaac A. Silva, Brazil	
284	COMPARISON OF CLASSIC CATHETER INSUFFLATION TECHNIQUE AND VENTILATOR DERIVED CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) FOR APNEA TESTING IN THE DIAGNOSIS OF BRAIN DEATH IN PATIENTS WITH POOR BASELINE LUNG FUNCTION – PRIMARY REPORT Joanna Solek Pastuszka, Poland	
285	THE TRANSPLANTATION OF ORGANS FROM DECEASED DONORS DUE TO IRREVERSIBLE CARDIAC ARREST IN POLAND IN 2013 AND 2014. Edyta Skwirczyńska-Szalbierz , Poland	

15:30-16:30	Oral Presentation: Family Care Grand Ballroom
	Chairs: Tina A. Coco, Australia and Hyunjin Kang, Korea
290	FAMILY KNOWLEDGE OF PATIENTS' ORGAN AND TISSUE DONATION WISHES AFFECTS CONSENT RATE Vanessa M. White, Australia
291	EVALUATION OF DEPRESSION IN DECEASED ORGAN DONOR FAMILY Gahee Kim, Korea
292	THE INFLUENCE OF MOTHERS IN FAMILY DECEASED ORGAN DONATION DECISIONS Holly L. Northam , Australia
293	UNDERSTANDING THE AUSTRALIAN DONOR FAMILY EXPERIENCE Eva Mehakovic , Australia
294	FACTORS INFLUENCING ON FAMILIES' CONSENT FOR ORGAN DONATION IN KOREA Hyunjin Park , Korea
295	MOTIVATIONS, CHALLENGES, AND ATTITUDES TO SELF-MANAGEMENT IN KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW OF QUALITATIVE STUDIES Camilla S. Hanson, Australia
15:30-16:30	Oral Presentation: Transmission of Disease Grand Ballroom II
	Chair: Michael G. Ison, United States and Su-Kil Park, Korea
300	KIDNEY TRANSPLANTATION FROM THIN BASEMENT MEMBRANE NEPHROPATHY DONOR Chanjoong Choi , Korea
301	DONOR-DERIVED STRONGYLOIDIASIS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS: A REVIEW AND POOLED ANALYSIS Jong Hun Kim , United State
302	TRANSMISSION OF RABIES VIRUS FROM A DECEASED ORGAN DONOR TO SIX RECIPIENTS IN KUWAIT AND SAUDI ARABIA Mustafa S.A. Al Mousawi , Kuwait
303	PSA POSITIVE DECEASED DONOR – PATOLOGIST INDISPENSABLE. Marek Ostrowski, Poland

15:30–16:30	Oral Presentation: Tissue Donation Grand Ballroom
	Chairs: Nam-Joon Yi, Korea and Kevin O'Connor, United States
309	USE OF THE HARMONIC SCALPEL IN THE RAPID EN BLOC RETRIEVAL OF THE LIVER AND PANCREAS FOR TRANSPLANTATION COLON THE WESTMEAD TECHNIQUE Henry C. Pleass , Australia
310	TISSUE RECOVERY AUTHORIZED BY DONOR REGISTRY PRIOR TO FAMILY CONSENT: A SINGLE US ORGAN PROCUREMENT ORGANIZATION PILOT PROJECT Steven M. Rudich, United States
311	RETROSPECTIVE ANALYSIS OF THE MASTER DEGREE IN DONATION AND TRANSPLANTATION OF ORGANS, TISSUES AND CELLS (D&T) Chloë Ballesté, Spain
312	DEVELOPMENT OF ELEARNING PROFESSIONAL EDUCATION TO INCREASE DONATION IN DEATHS OCCURRING OUT OF HOSPITAL Kimberly P. Young, Canada
313	HONORING FIRST-PERSON AUTHORIZATION: RECOVERING TISSUE PRIOR TO OBTAINING A MEDICAL/SOCIAL HISTORY Simon S. Keith, United States
314	THE BENEFITS OF TRANSPLANT PROCUREMENT MANAGEMENT (TPM) TRAINING ON PROFESSIONAL COMPETENCE DEVELOPMENT AND CAREER EVOLUTIONS OF DONATION AND TRANSPLANT RELATED HEALTH CARE WORKERS Chloë Ballesté, Spain
16:30–18:00	Concurrent Symposium: Future of Donation Grand Ballroom
	Chairs: Myoung Soo Kim, Korea and Philippe Morel, Switzerland
320	HSCT WITH ORGAN TRANSPLANTATION John D. Scandling, United States
321	TISSUE ENGINEERING IN CARDIOVASCULAR SURGERY Serghei Cebotari, Germany
322	DONOR GENES AND TRANSPLANT OUTCOME Mark D. D. Stegall, United States
323	XENOTRANSPLANTATION Chung-Gyu Park, Korea

16:30-18:00	Concurrent Symposium: Organ Allocation Policy	Grand Ballroom II
	Chairs: In-Sung Moon, Korea and Thomas D. Mone, United States	
330	HEART AND LUNG Andre Simon, United Kingdom	
331	LIVER Myoung Soo Kim , Korea	
332	KIDNEY Alan B. Leichtman, United States	
333	VASCULARIZED COMPOSITE ALLOGRAFT Stefan Schneeberger, Austria	
16:30-18:00	Concurrent Symposium: Quality Improvement	Grand Ballroom III
	Chairs: Susan Gunderson, United States and Kyung-Suk Suh, Korea	
340	THREE CLINICAL TRIALS I WOULD LIKE TO SEE HAPPEN John S. Gill, Canada	
341	DONOR FACTORS Dorry L. Segev, United States	
342	ODEQUS HOSPITAL QUALITY INDICATORS IN DBD, DCD AND LD. EU PROJEG Marti Manyalich, Spain	СТ
343	QUALITY CONTROL Timothy L. Pruett, United States	
16:30–18:00	Oral Presentation: Donation after Circulatory Death	Studio I-II
	Chairs: Young Hoon Kim, Korea and Paul Murphy, United Kingdom	
350	MACHINE PULSATILE PERFUSION PARAMETERS AND HISTOLOGICAL FINDINGS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL OF THROMBOLYTIC THERAPY FOLLOWING DCD KIDNEY DONATION. Kenneth J. Woodside , United States	
351	THE COMBINED PREDICTIVE VALUE OF THE ECD CRITERIA FOR LONG-TERM GRAFT SURVIVAL OF KIDNEYS FROM DONORS AFTER CARDIAC DEATH: A SINGLE-CENTER EXPERIENCE OVER THREE DECADES Mamoru Kusaka, Japan	I
352	ORGAN DONATION IN POLAND; NUMBERS, INDICATORS AND TREND ESTIN Jarosław Czerwiński, Poland	MATION
353	EXCELLENT POSTTRANSPLANT OUTCOME OF RENAL TRANSPLANTS ENGRADED KIDNEYS RETRIEVED USING IN SITU REGIONAL COOLING TECHNIQUE. A 24 YEAR SINGLE-CENTER EXPERIENCE IN JAPAN Hitomi Sasaki, Japan	

354	OVERCOMING HOSPITAL RESISTANCE TO CREATE A SUCCESSFUL DONATION AFTER CIRCULATORY DEATH PROGRAM Rosemary A. O'Meeghan, United States
355	THE LONG-TERM OUTCOMES OF KIDNEY TRANSPLANTATION FROM DONATION AFTER CIRCULATORY DEATH DURING BRAIN DEATH DONOR EVALUATION IN A SINGLE CENTER IN KOREA Dong Kyu Oh , Korea
356	DOES DONOR SERUM CREATININE IN DONATION AFTER CARDIAC DEATH CASES IMPACT THE LONG TERM OUTCOME IN KIDNEY TRANSPLANTATION? Juntaro Ashikari, Japan
357	WHAT IS THE MAXIMUM POTENTIAL FOR DONATION AFTER CIRCULATORY DEATH IN AUSTRALIA? David V. Pilcher, Australia
358	OVER 1600 DCD ORGANS TRANSPLANTED IN 20 YEARS: AN EFFECTIVE ORGAN PROCUREMENT ORGANIZATION'S DCD PROGRAM INCREASES THE DONOR POOL Howard M. Nathan. United States

18:00-19:00	Poster Session 1 on Allocation, QM and Law	Level 5F
	Chair: Susan Gunderson, United States	
360	WAITING FOR KIDNEY TRANSPLANTATION: A LIVED EXPERIENCE OF PATIENTS WITH END-STAGE RENAL DISEASE IN KOREA Hye Jin Chong, Korea	
361	APPLICATION OF WEB-BASED CALCULATOR PREDICTING DELAYED GRAFT FUNCTION ON DECEASED DONOR RENAL TRANSPLANTATION IN THE KOREAN POPULATION Mihyeong Kim, Korea	
362	HLA CLASS II ANTIGEN MATCHING EFFECT ON KIDNEY TRANSPLANTATION Yong W. Cho , United States	
363	THE ADJUSTING EXPERIENCE OF KIDNEY TRANSPLANTATION RECIPIENTS IN KO Sunyoung Son, Korea	DREA
364	THE ANALYSIS OF DISCARDED DECEASED ORGANS IN KSA Faissal A.M. Shaheen, Saudi Arabia	
366	ASSESSMENT OF POTENTIAL ORGAN DONATION IN SINGLE INSTITUTE Won Jung Lee , Korea	
367	PREDICTION OF RECIPIENTS SURVIVAL IN DECEASED DONOR KIDNEY TRANSPLANT USING KOREAN NETWORK FOR ORGAN SHARING DATABASE Kyung Don Yoo , Korea	

18:00-19:00	Poster Session 2 on Intensive Care and Donor Management	Level 5F
	Chair: Kimberly P. Young, Canada	
368	UNPREDICTED DISSEMINATED CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION: CASE REPORT Jai Young Cho, Korea	R
369	ACTIVATED DECEASED ORGAN DONATION AND TRANSPLANTATION BY AN INTENSIVIST IN EWHA UNIVERSITY 2013-2015 Young Joo Lee, Korea	
370	FACTORS DELAYING ORGAN PROCUREMENT AFTER DECLARATION OF BRAIN Suejin Kim , Korea	I DEATH
371	THE STRESS FOR ORGAN TRANSPLANTATION COORDINATORS IN THE PROCE OF MANAGING THE BRAIN-DEAD Bok Nyeo Kim , Korea	SS
372	EN-BLOC TRANSPLANTATION OF HORSESHOE KIDNEY IN KOREA Jun Bae Bang , Korea	
373	THE EXPERIENCE OF DONATION COORDINATOR Hyun Jung Kim , Korea	
374	THE BENEFICIAL EFFECT OF EXTRACORPOREAL MEMBRANE OXYGENATOR (ECMO) TO RETRIEVAL ORGAN PERFUSION DURING UNSTABLE BRAIN DEATH DONOR MANAGEMENT – CASE REPORT Jeong Hee Kang, Korea	1
375	HOW TO INCREASE ORGAN DONATION IN SWEDEN Carin B. Franzén, Sweden	
376	THE CLINICAL IMPORTANCE OF INFERIOR VENA CAVA ANOMALY IN THE ORC DONATION SURGERY FROM A DECEASED DONOR Mihyeong Kim , Korea	SAN
377	A MYD88 INHIBITOR AS A POTENTIAL COMPONENT OF ORGAN CONSERVATI Hong Rae Cho, Korea	ON SOLUTION

18:00-19:00	Poster Session 3 on Living Donation	Level 5F
	Chair: Jongwon Ha, Korea	
378	FATE OF POTENTIAL LIVING DONORS FOR LIVER TRANSPLANTATION Ok Kyung Kim, Korea	
380	THE QUALITY OF LIFE IN LIVING DONORS AFTER LIVER TRANSPLANTATION Seungheui Hong , Korea	
382	6 EXPERIENCES OF KIDNEY TRANSPLANTS FROM HEPATITIS B ANTIGEN POSITIVE LIVING DONOR TO ANTIGEN NEGATIVE RECIPIENTS Byung Hyun Choi , Korea	
383	EXPERIENCE OF LIVING DONORS FOR SMALL BOWEL TRANSPLANTATION Hyung Sook Kim , Korea	
384	A STUDY ON THE LIVING ORGAN DONORS' DECISION-MAKING, CONCERNS, AMBIVALENCE, AND MOTIVATION ABOUT THE DONATION Yunmi Lee , Korea	
385	REASONS FOR FAILURE TO COMPLETE THE PROCESS TO BECOME A LIVING KIDNEY DONOR Joyce A. Trompeta, United States	
386	LONG TERM OUTCOMES AFTER DONATION IN LIVING DONOR LIVER TRANSPLANTATION: LIVER FUNCTION INCLUDING PLATELET COUNTS, AND SOCIO-ECONOMICAL AND PSYCHOLOGICAL SITUATION Kyung-Suk Suh , Korea	
387	CHARACTERISTICS AND OUTCOMES OF LIVING KIDNEY DONORS Hye Jin Lim , Korea	
388	THE STRESS AND EDUCATIONAL NEED OF PATIENTS IN ABO INCOMPATIBLE LIVING KIDNEY TRANSPLANTATION Hyung Sook Kim, Korea	
389	FACTORS REQUIRED FOR TRANSPLANT COORDINATORS TO IMPLEMENT A COMPREHENSIVE SUPPORT FOR TRANSPLANT RECIPIENTS Miho Shingu , Japan	

07:30-08:30	Early Morning Symposium: Family Care	Grand Ballroon
	Chairs: Sungwon Na, Korea and Helen I. Opdam, Australia	
400	DONOR FAMILY CARE - THE JOURNEY AFTER THE "YES" Tina A. Coco , Australia	
401	FAMILY APPROACH AND CONSENT OBTAINMENT Helen I. Opdam , Australia	
402	END OF LIFE CARE (DNR AND ORGAN DONATION) Sungwon Na, Korea	
07:30-08:30	Early Morning Symposium: Crisis Management of Donor	Studio I-II
	Chairs: Louis Beaulieu, Canada and Sang Young Chung, Korea	<u>'</u>
410	CIRCULATORY MANAGEMENT Stephen Beed, Canada	
411	STATE-OF-ART, "HORMONAL REPLACEMENT IN BRAIN DEAD ORGAN DON AND THE SCIENCE BEHIND. Dimitri 0. Novitzky , United States	IORS",
412	CRISES IN MANAGING PAEDIATRIC DONORS Thomas Nakagawa , United States	
413	PULMONARY MANAGEMENT Stephen Beed, Canada	
08:30-10:30	Plenary: Tissue Donation	Grand Ballrooi I-II-III
	Chairs: Won-Hyun Cho, Korea and Jongwon Ha, Korea	
420	HOW TO IMPROVE TISSUE DONATION? Howard M. Nathan, United States	
421	SAFETY ASPECTS OF TISSUE DONATION Marisa R. Herson, Australia	
422	QUALITY CONTROL IN TISSUE BANKING George A Herrera, United States	
423	TRACEABILITY Scott A. Brubaker, United States	
	Coffee Break	Park Ballroon

11:00-12:30	Oral Presentation: Quality and Data Management Grand Ballroom
	Chairs: Chang Kwon Oh, Korea, and Thomas D. Mone, United States
430	ORGAN DONATION WORKFLOWS – WHAT OWNERSHIP ENTAILS Rosemary A. O'Meeghan, United States
431	ACHIEVING 50 PERCENT GROWTH IN ORGAN DONORS OVER HISTORICAL AVERAGE: ONE ORGAN PROCUREMENT ORGANIZATION'S STRATEGY FOR SAVING MORE LIVES Jeffrey P. Orlowski , United States
432	FACTORS INFLUENCING FAMILIES' REFUSAL FOR DECEASED ORGAN AND TISSUE DONATION IN MALAYSIA Naren Kumar Surendra, Malaysia
433	IRODaT, THE INTERNATIONAL REGISTRY IN ORGAN DONATION AND TRANSPLANTATION Maria P. Gomez , Australia
434	PREDICTING THE NUMBER OF ORGAN DONORS IN AUSTRALIAN HOSPITALS - IMPLICATIONS FOR MONITORING ORGAN DONATION PRACTICES David V. Pilcher , Australia
435	MELD REPRODUCIBILITY IN ARGENTINA Liliana E. Bisigniano , Argentina
436	LIVING ORGAN DONATION HIGH QUALITY PRACTICES: LIDOBS NETWORK RECOMMENDATIONS Ana Teresa T. Menjivar, Spain
437	IMPLEMENTING THE GOSBAR COLOUR SCHEME IN ORGAN DONATION TRUST/BOARD REPORTS IN THE UK Paul Murphy, United Kingdom
438	WEB BASED SURVEY OF HOSPITAL PERSONNEL CONDUCTED IMMEDIATELY FOLLOWING CASES PROVIDES AN OPO WITH IMPORTANT PRACTICE AND PERFORMANCE IMPROVEMENT DATA Richard Hasz, United States
11:00-12:30	Oral Presentation: Improving Knowledge Grand Ballroom
	Chair: Maria Siemionow, United States and Jae Berm Park, Korea
440	"DONATION CHAMPION" TRAINING SESSIONS FOR HOSPITAL PERSONNEL INCREASES REFERRALS WHILE DRAMATICALLY DECREASING THE NUMBER OF MISSED REFERRALS Kathy P. Yandle, United States
441	COMPETITIVE HOSPITAL CHALLENGE CONTRIBUTES TO INCREASE IN DONOR DESIGNATION AND INFORMS FUTURE STRATEGIES AIMED AT INCREASING DONATION RATES John D. Green, United States

442	IMPLEMENTATION OF HOSPITAL-WIDE ELEARNING TRAINING PROGRAM RESULTS IN DECREASED RATE OF DELAYED TISSUE DONOR REFERRALS AND IMPROVED TISSUE DONATION OUTCOMES Kathy P. Yandle, United States
443	eLEARNING OFFERS FLEXIBILITY AND ON-DEMAND ACCESS FOR DONATION PROFESSIONALS AROUND THE WORLD Theresa A. Daly , United States
444	HOW eLEARNING IS UTILIZED TO HELP DONATION PROFESSIONALS CONDUCT THE DONOR RISK ASSESSMENT INTERVIEW (DRAI) Theresa A. Daly, United States
445	A COMPARISON OF HISPANIC'S AND NON-HISPANICS' ORGAN DONATION EXPERIENCE Michael Adair-Kriz , United States
446	THE CONCEPT OF BRAIN DEATH AND ORGAN DONATION IS WELL UNDERSTOOD BY AGE OF 11 YEARS: A STUDY FROM INDIA Avnish K. Seth , India
447	MANAGING A COMMUNICATIONS CENTER THAT SUPPORTS ALL MISSION CRITICAL FUNCTIONS OF A HIGH VOLUME ORGAN PROCUREMENT ORGANIZATION (OPO) John P. Clarke , United States
448	IMPACT OF PROFESSIONAL EDUCATION ON HOSPITAL STAFF KNOWLEDGE & BELIEFS Vanessa M. White, Australia
11:00-12:30	Oral Presentation: Best Practices in Donation Grand Ballroom III
	Chairs: Sang II Kim, Korea and Haibo Wang, Hong Kong
450	UNDERSTANDING OTD REQUESTING PRACTICE: EVALUATION OF FLEXIBLE PRACTICE IN A COMPLEX ENVIRONMENT Virginia Lewis, Australia
451	THE DEVELOPMENT OF ORGAN DONATION SYSTEM AT UDON THANI HOSPITAL, THAILAND

	Chairs: Sang II Kim, Korea and Haibo Wang, Hong Kong
450	UNDERSTANDING OTD REQUESTING PRACTICE: EVALUATION OF FLEXIBLE PRACTICE IN A COMPLEX ENVIRONMENT Virginia Lewis , Australia
451	THE DEVELOPMENT OF ORGAN DONATION SYSTEM AT UDON THANI HOSPITAL, THAILAND Sasipin Mongkolchai , Thailand
452	UNDERSTANDING DECEASED DONORS WITH ZERO ORGANS RECOVERED Jeffrey D. Punch , United States
453	THE EFFECT OF THE DONATION IMPROVEMENT PROGRAM IN KOREA Hwajung Lee , Korea
454	USABILITY OF THE RAPID ASSESSMENT OF HOSPITAL PROCUREMENT BARRIERS IN DONATION (RAPID) AS A TOOL FOR OPO HOSPITAL DEVELOPMENT STAFF Heather M. Traino , United States
455	EXPANDING BEST PRACTICES IN A DONOR HOSPITAL Rosemary A. O'Meeghan, United States

	12:30-13:30	Lunch Break	Level 3F
	468	NATIONAL TRANSPLANTATION PREGNANCY REGISTRY (NTPR): PREGNANCY AFTER TRANSPLANTATION Caitlin Clarke, United States	
	467	SUCCESS FACTORS TO INCREASE THE NUMBER OF ORGAN DONATIONS- FROM THE ORGANIZATIONAL PERSPECTIVES Yoko Uryuhara , Japan	
	466	RENAL TRANSPLANTATION WITH DONORS OVER 60 YEARS OF AGE: CLINICA Jacques Malaise , Canada	L OUTCOME
	465	A STUDY ON KOREAN DECEASED KIDNEY DONORS' DONOR QUALITY USING Jaesook Oh , Korea	KDRI
	464	BIOCOMPATIBILITY SAFETY ASSESSMENT OF DECELLULARIZED PORCINE KIDNEY SCAFFOLDS FOR XENOTRANSPLANTATION Kamal H. Hussein , Korea	
	463	EXTENDING SUCCESSFUL RESULTS OF NPOM (NEW PERSIAN OPU MODEL) TO ALL UNIVERSITIES OF IRAN Katayoun Najafizadeh , Iran (Islamic Republic of)	
=	462	EVALUATION OF ORGAN DYSFUNCTION CASES USING THE KIDNEY DONOR RISK INDEX (KDRI) Myounghwa Lee, Korea	
	461	ATTITUDE TO BRAIN DEATH ORGAN DONATION AND THE REPORTING OF POTENTIAL BRAIN DEATH – FOCUSING ON DIP NON – AGREEMENT HOSPITAL Jungsu Hong , Korea	.S
	460	FIRST YEAR DATA EVALUATING THE UTILITY OF A FULL-TIME OPO STAFF RECOVERY SURGEON Patricia A. Niles, United States	
		Chairs: Hong Rae Cho, Korea and Kerstin Moench, Germany	
	11:00-12:30	Oral Presentation: Quality Management	Studio I-II
	458	CURRENT STATUS OF DECEASED ORGAN DONATION IN JAPAN Atsushi Aikawa, Japan	
	457	DEVELOPMENT OF PROTOCOL FOR DECEASED KIDNEY TRANSPLANTATION RECIPIENTS WHILE WAITING FOR KIDNEY TRANSPLANTATION Hyun Jung Kim , Korea	
	456	DO NEXT OF KIN OR THE DECEASED REFUSE ORGAN DONATION – A NATIONAL REGISTRATION Monika Olofsson Storrø , Norway	

13:30-14:20	Plenary: Keynote Lecture	Grand Ballroom I-II-III
	Chairs: Günter Kirste, Germany and Jongwon Ha, Korea	
470	ORGAN AND TISSUE REGENERATION	
	James J. Yoo, United States	
14:20-14:30	Coffee Break	Park Ballroom Foyer Area
14:30–16:00	Oral Presentation: Intensive Care	Grand Ballroom
	Chairs: Dariusz J. Patrzalek, Poland and Dong-Chan Kim, Korea	
480	THE CHANGING CRITICAL CARE ENVIRONMENT PROMPTS THIS ORGAN PROCUREMENT ORGANIZATION TO IDENTIFY SIX SCENARIOS FOR APPROAFAMILIES ABOUT ORGAN DONATION OPPORTUNITIES Caitlin Clarke, United States	ACHING
481	OPPORTUNITIES FOR IMPROVEMENT IN AN EVER-CHANGING POOL OF POTENTIAL DONORS Richard Hasz, United States	
482	ANALYSIS OF CAUSES FOR INTERRUPTION IN PROCESS OF BRAIN DEATH N Jeong Lim Lee , Korea	IANAGEMENT
483	SWEDISH INTENSIVE CARE NURSES ATTITUDES TOWARDS ORGAN DONOR Anne Floden , Sweden	ADVOCACY
484	ATTITUDES TOWARDS ORGAN DONOR ADVOCACY AMONG SWEDISH INTE AND CRITICAL CARE NURSES: A SUMMARY OF A DOCTORAL DISSERTATION Anne Floden , Sweden	
485	IMPACT OF A COLLABORATIVE REQUESTING MODEL (CRM) ON PRACTICE A CONSENT RATES WHERE THE PATIENT'S WISHES ARE KNOWN AND NOT KN Virginia Lewis, Australia	
486	A COLLABORATIVE APPROACH TO REQUESTING SUPPORTS GOOD PRACTIC INCREASES CONSENT RATES: RESULTS OF A NATIONAL PILOT OF ORGAN D REQUESTING MODELS IN AUSTRALIA Virginia Lewis , Australia	
487	NORMALISING ORGAN DONATION CONVERSATIONS AS PART OF ROUTINE LIFE CARE IN THE INTENSIVE CARE UNIT: EVERY FAMILY, EVERY TIME Leanne M. McEvoy , Australia	END OF
488	THE IMPACT OF HYDROXYETHYL STARCH USE IN RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION Sang Jun Park, Korea	

14:30-16:00	Oral Presentation: Education in Organ Donation
	Chairs: Dong-Sik Kim, Korea, and Theresa A. Daly, United States
490	MANAGEMENT TOOLS OF A COMMISSION-HOSPITAL DONATION OF ORGANS AND TISSUES: PROFILE OF THE NURSING TEAM. Luiz Gustavo Torres Dias da Curz , Brazil
491	TRANSPLANT PROCUREMENT MANAGEMENT (TPM) MODEL TRAINING; DRAMATIC REFORM OF THE MINDSET OF HEALTH CARE PROFESSIONALS IN HYOGO PREFECTURE, JAPAN Mikiko Yoshikawa , Japan
492	POSTGRADUATE STUDIES FOR TRANSPLANT COORDINATORS AT MEDICAL UNIVERSITY OF WARSAW; 8 YEARS OF EXPERIENCE, OVER 400 GRADUATES Jarosław Czerwiński, Poland
493	FAMILY COMMUNICATION AND AUTHORIZATION TRAINING INCREASES DONATION PROFESSIONALS' KNOWLEDGE AND CONFIDENCE IN CONDUCTING THE DONATION CONVERSATION Theresa A. Daly, United States
494	THE REASONS FOR DENIAL OF ORGAN DONATIONPOTENTIAL BRAIN DEAD PATIENT'S FAMILY Youngsoon Yeong, Korea
495	SURGICAL RESIDENT TRAINING ON EXPLAINING BRAIN DEATH IMPROVES ORGAN DONATION PERFORMANCE Howard M. Nathan, United States
496	PROMOTING CULTURAL CHANGE THROUGH PROFESSIONAL EDUCATION Eva Mehakovic , Australia
497	A COMPARISON OF THE QUALITY AND CONTENT OF COMMUNICATION IN REQUESTS FOR ADULT AND PEDIATRIC ORGAN DONATION Heather M. Traino , United States
498	GEOGRAPHIC VARIATION IN THE PROCESS AND OUTCOMES OF REQUESTS FOR SOLID ORGAN DONATION Heather M. Traino , United States
14:30-16:00	Oral Presentation: Allocation Grand Ballroom
	Chair: Alan B. Leichtman, United States and Joong-Kyung Kim, Korea
500	RESULTS OF DECEASED DONOR KIDNEY TRANSPLANTATION IN YOUNG RECIPIENTS AFTER AGE-MATCHED AND MISMATCHED (OLD-TO-YOUNG) TRANSPLANTATION Janis Jushinskis, Latvia
501	POSITIVE RATES OF PRELIMINARY CROSSMATCHES AMONG TRANSPLANT CANDIDATES WAITLISTED FOR DIFFERENT ORGANS IN THE KOREAN NETWORK FOR ORGAN SHARING Myoung Hee Park, Korea

Detailed Program: Day 3

502	BROADER LIVER ALLOCATION: ONE ORGAN PROCUREMENT ORGANIZATION'S EXPERIENCE IN THE SHARE 35 ERA Jeffrey P. Orlowski, United States	
503	MOVING TOWARDS GREATER ACCEPTANCE OF OLDER DONORS IN AUSTRALIA Helen I. Opdam , Australia	
504	CORNEA TRANSPLANTATION IN BANGLADESH: WHO DO THE EYE BANKS SEI Mir M. Rahman , Bangladesh	RVE?
505	IMPLEMENTATION OF THE NATIONAL INSTITUTE OF HEALTH COMMON FUN GENOTYPE-TISSUE EXPRESSION PROJECT WITHIN AN ORGAN PROCUREMEN ORGANIZATION THROUGH COLLECTION OF HUMAN TISSUE SAMPLES FROM ORGAN & TISSUE DONORS John P. Clarke, United States	NT
506	UTILIZATION OF KIDNEYS FROM HCV SEROPOSITIVE DONORS IN THE U.S. Richard Hasz , United States	
507	NEW FUNDAMENTAL APPROACH OF KIDNEY ALLOCATION IN IRAN Shadi Shafaghi , Iran (Islamic Republic of)	
508	NEW MANUAL HEART ALLOCATION METHOD IN IRAN Shadi Shafaghi, Iran (Islamic Republic of)	
14:30-16:00	Oral Presentation: Donation after Brain Death	Studio I-II
	Chairs: Faissal A.M.Shaheen, Saudi Arabia and Jae-Won Joh, Korea	
510	IROSS: IRANIAN OPU`S SUPPORTING SYSTEM Omid Ghobadi, Iran (Islamic Republic of)	
511	SIGNIFICANT INCREASE IN THE RATE OF POTENTIAL DONOR DETECTION BY PPDDP (PERSIAN POSSIBLE DONOR DETECTION PROGRAM) Omid Ghobadi, Iran (Islamic Republic of)	USING
512	ORGAN PROCUREMENT FROM DECEASED EXPATS IN KUWAIT Mustafa S.A. Al Mousawi , Kuwait	
513	OUTCOMES OF KIDNEY RECIPIENTS ACCORDING TO PRE-TRANSPLANTATION RENAL REPLACEMENT THERAPY Jae Geun Lee, Korea	N
514	AUSTRALIA'S ROLE IN SUPPORTING THE INTRODUCTION OF DECEASED ORC DONATION AND KIDNEY TRANSPLANTATION IN NEW CALEDONIA	SAN

PANCREAS RETRIEVAL AND SUCCESSFUL TRANSPLANT ACROSS THE

Richard D. M. Allen, Australia

AUSTRALIAN CONTINENT **Sara Shahrestani**, Australia

515

516	PROGRAM OF TRANSPLANT ORGANIZATION TO COORDINATE THE DEVELO OF ORGAN DONATION IN KAZAKHSTAN Marlen Doskali , Kazakhstan	PMENT
517	ANALYSIS OF ORGAN DONATION TIME FROM BRAIN-DEAD DONORS FOR VASCULARIZED COMPOSITE TISSUE ALLOTRANSPLANTATION PREPARATION Jong Won Hong, Korea	N IN KOREA
518	THE IMPACT OF TIMELY NOTIFICATION AND EFFECTIVE REQUESTING PROTO ON ORGAN DONATION CONVERSION RATES Kathy P. Yandle , United States	OCOLS
16:00-16:30	Coffee Break	Park Ballroom Foyer Area
16:30-18:00	Concurrent Symposium: Paired Donation	Grand Ballroom I
	Chairs: Michael A. Bos, The Netherlands and Oh Jung Kwon, Korea	
520	KOREA - DEVELOPMENT OF CONCEPT AND CURRENT SITUATION Soon-II Kim , Korea	
521	USA - NATIONWIDE EXTENSION OF PAIRED DONATION PROGRAM Adam W. Bingaman , United States	
522	FROM PAIRED DONATION TO ABO-I KIDNEX TRANSPLANTATION - EUROPEAN EXPERIENCE Günter Kirste , Germany	
523	WHAT IS THE BEST OPTION FOR SENSITIZED OR ABO-INCOMPATIBLE RECIP PAIRED DONATION OR DESENSITIZATION? Kazunari Tanabe, Japan	IENTS?
16:30-18:00	Concurrent Symposium: Mass Media	Grand Ballroom II
	Chairs: lk Jin Yun, Korea and Helen I. Opdam, Australia	•
530	SOCIAL NETWORKING SERVICE (BLOG, TWITTER, FACEBOOK) Susan Mau Larson, United States	
531	BROADCAST (TV AND RADIO) Thomas D. Mone , United States	
532	TELLING THE STORY OF DONATION Kent Holloway, United States	
533	CAMPAIGNS TO PROMOTE ORGAN TRANSPLANTATION AND DONATION IN Norihide Fukushima , Japan	JAPAN

16:30-18:00	Round-Table: China, Hong Kong, India, Japan, Taiwan, Thailand	Studio I-II
	Chair: Francis L. Delmonico, United States	
540	PERSPECTIVE FROM JAPAN Naoshi Shinozaki, Japan	
541	PERSPECTIVE FROM TAIWAN Po-Chang Lee, Taiwan	
542	PERSPECTIVE FROM THAILAND Visist Dhitavat, Thailand	
543	PERSPECTIVE FROM HONG KONG Jenny Koo, Hong Kong	
544	PERSPECTIVE FROM INDIA Sunil Shroff, India	
545	PERSPECTIVE FROM CHINA Li Li , People's Republic of China	
18:00-19:00	ISODP Business Meeting and Awards	Studio I-II
18:00-19:00	Poster Session 4 on Education and Communication	Park Ballroom Foyer Area
	Chair: S.A. Anwar Naqvi, Pakistan	
550	DEVELOPMENT OF KIDNEY DONOR EDUCATIONAL MATERIALS ON PRE-POST KIDNEY TRANSPLANTATION Sunyoung Son, Korea	
551	THE VARIATION IN THE REPORTING RATE AFTER THE DEVELOPMENT AND APPLICATION OF THE MOBILE PROGRAM FOR REPORTING POTENTIAL BRAIN-DEAD ORGAN DONORS Cha Sora, Korea	
552	QUESTIONING ORGAN DONATION QUESTIONNAIRES: WHOSE VIEWS ARE CO Dominique E. Martin , Australia	OUNTED?
553	ROLE OF SPORTS GAMES IN SOLVING THE SELF-SUFFICIENCY OF ORGAN DONATION Won-Hyun Cho , Korea	
555	THE EFFECT OF EDUCATION PROGRAM FOR COORDINATORS' ATTITUDE ABO DECEASED DONOR'S FAMILY CARE IN SOUTH KOREA Jinsook Yu , Korea	TUC
556	THE EDUCATION EFFECT OF ORGAN DONATION AND TRANSPLANTATION O HIGH SCHOOL STUDENTS Jinsook Yu, Korea	N

557	CHANGE OF ATTITUDE FOR ORGAN DONATION AFTER BRAIN DEATH ACCORDING TO VERBAL EDUCATION AND USE OF PROPAGANDA VIDEO CLIP Hye Yeon Jang , Korea
558	THE SUCCESS OF THE TRIPOD TEAM AT NEVADA DONOR NETWORK Joseph Ferreira, United States
559	ANGELS OF CHANGE - STUDENT VOLUNTEERS FOR ORGAN DONATION Pallavi Kumar , India
18:00-19:00	Poster Session 5 on Determination of Brain Death Park Ballroom Foyer Area
	Chair: Dariusz J. Patrzalek, Poland
560	FACTORS OF POTENTIAL DONORS DID NOT BECOME ACTUAL DONORS IN TEN YEARS Jidapha Waisaya , Thailand
561	AN ANALYSIS ON THE STATUS OF DECEASED DONORS IN AMC Saerom Lee, Korea
562	ADJUSTMENT TO THE CALCULATION OF THE NEUROLOGICAL DEATH TESTING RATE IN THE UK Paul Murphy , United Kingdom
565	EUROPEAN EDUCATIONAL INITIATIVE THROUGH TPM-DTI FOR BETTER DONATION AND TRANSPLANTATION RESULTS IN THE REPUBLIC OF MOLDOVA Chloë Ballesté, Spain
566	KIDNEY DONATION FROM THE PATIENT WHO UNDERWENT ENDOVASCULAR ANEURYSM REPAIR Sang Jun Park, Korea

18:00-19:00	Poster Session 6 on Tissue Donation and Banking Park Ballroom Foyer Area
	Chair: Faissal A.M. Shaheen, Saudi Arabia
563	ACTIVITY OF EAST JAPAN TISSUE TRANSPLANTATION NETWORK (EJTTN) AND DONOR STATISTICS: IMPLICATIONS FOR FURTHER ENHANCEMENT OF TISSUE DONATION IN THE REGION Yumi Akashi, Japan
564	DECEASED ORGAN DONATION AND TRANSPLANTATION ACTIVITY IN THE KINGDOM OF SAUDI ARABIA; A 20 YEAR PERSPECTIVE: 1995 TO 2004 VERSUS 2005 TO 2014 Faissal A.M. Shaheen, Saudi Arabia
570	AN ANALYSIS OF THE DATA ON TISSUE DONATION FOLLOWING BRAIN DEATH IN SAMSUNG MEDICAL CENTER Sunmi Baek, Korea
571	REGIONAL SURVEY OF TISSUE DONATION IN PUBLICS AND MEDICAL STAFFS AROUND OSAKA Mayuko Ogawa, Japan
572	BIOLOGICAL RESPONSES IN THE PIG TO RABBIT TRACHEA XENOTRANSPLANTATION MODEL ${\bf Jae\ Yeon\ Lee}, {\bf Korea}$
573	EFFECTS OF IMMUNOSUPPRESSIVE THERAPY FOR TRACHEAL TRANSPLANTATION USING NATIVE TRACHEA-MIMETIC BELLOWS SCAFFOLDS IN A RABBIT MODEL Jae Yeon Lee, Korea
574	SUCCESSFUL TRACHEAL XENOTRANSPLANTATION WITH FRESH PORCINE TRACHEAS IN A BEAGLE MODEL Jae Yeon Lee, Korea
575	ABDOMINAL HERNIA REPAIR SURGERY WITH THE NEW INJECTABLE POLYMER BIOMATERIALS Edyta Skwirczyńska-Szalbierz, Poland
576	ASSESSMENT OF THE DEGREE OF MHC MATCHING IN DOG FOR PRECLINICAL STUDY OF ORGAN TRANSPLANTATION Dong-Gyu Lee , Korea
579	ACTIVITY OF THE UNIVERSITY OF TOKYO TISSUE BANK (UTTB): AN 18-YEAR SCORE CARD Yumi Akashi , Japan
19:30–21:00	Congress Dinner Grand Ballroom

Notes

08:30-10:30	Plenary: Living Donation Grand Ballro 1-II-III	om
	Chairs: S.A. Anwar Naqvi, Pakistan and Dong Goo Kim, Korea	
600	WHAT OUTCOMES MATTER TO DONORS? Allison Tong, Australia	
601	EXTENDED CRITERIA IN LIVING DONATION Dorry L. Segev , United States	
602	REHABILITATION AND LONG TERM FOLLOW UP OF LIVING DONOR John S. Gill , Canada	
603	DONOR FAMILY INTERACTION S. A. Anwar Naqvi, Pakistan	
10:30-11:00	Coffee Break Park Ballrog Foyer Are:	ea e
11:00-12:30	Oral Presentation: Organization of Organ Donation Grand Ballro	om
	Chairs: Sang-Il Min, Korea and Haibo Wang, Hong Kong	
610	QUALITY INDICATORS OF IMPACT IN THE PROCESS OF ORGAN AND TISSUE DONATION Luiz Gustavo Torres Dias da Curz , Brazil	
611	AN EFFECTIVE SOCIAL MEDIA STRATEGY TO PROMOTE AWARENESS AND ENGAGEMENT INCREASES PUBLIC EDUCATION AND DONOR DESIGNATIONS John D. Green , United States	
612	ENGAGING WITH RELIGIOUS AND FAITH COMMUNITIES: AUSTRALIA, ISLAM AND ORGAN DONATION Suzi M. Clark, Australia	
613	GREEN CORRIDOR FOR RAPID TRANSIT OF HEART FOR TRANSPLANTATION: A FIRST FOR NORTH INDIA. Avnish K. Seth , India	
614	ORGAN DONATION IN THE U.S.: THE TALE OF THE AFRICAN AMERICAN JOURNEY OF MOVING FROM THE BOTTOM TO THE TOP! Clive O. Callender, United States	
615	BIRTH WEIGHT AS A MARKER OF NEPHRON NUMBER: IMPLEMENTATION IN THE EDUCATION OF LIVING KIDNEY DONOR OUTCOMES? Thomas Schachtner, Germany	

616		ORGAN DONOR ALLOCATION SYSTEM FOR LIVER TRANSPLANTATION IN THE KINGDOM OF SAUDI ARABIA: CALL FOR MAJOR REVISION Mohammed Ibrahim Al Sebayel , Saudi Arabia
617		GROWING A SUCCESSFUL RELATIONSHIP BETWEEN AN ORGAN PROCUREMENT ORGANIZATION AND A CORONER/MEDICAL EXAMINER'S OFFICE Simon S. Keith , United States
618	N.	THE IMPACT OF CHRONIC PAIN, HYPERTENSION AND FATIGUE ON LONG-TERM QUALITY OF LIFE AFTER LIVING KIDNEY DONATION Thomas Schachtner , Germany

	Thomas Schachtner, Germany
11:00-12:30	Oral Presentation: Organ Preservation Grand Ballroom
	Chair: Andre Simon, United Kingdom and Hee Chul Yu, Korea
620	A RESEARCH AND DEVELOPMENT OF PERFUSION PRESERVATION MACHINE FOR MARGINAL GRAFT Naoto Matsuno, Japan
621	RENAL RESISTANCE MEASURED DURING PULSATILE PERFUSION AND LONG-TERM KIDNEY TRANSPLANT OUTCOMES Shaifali Sandal, Canada
622	THE EFFECT OF SYSTEMIC CATECHOLAMINE APPLICATION ON THE MICROCIRCULATION IN LIVER PROCUREMENT Mari Maesc Strempel, Germany
623	ELECTRONMICROSCOPIC EVALUATION OF DCD LIVERS PRESERVED BY MACHINE PERFUSION PRESERVATION Naoto Matsuno, Japan
624	REASONS OF KIDNEY DISCARD AFTER ALLOCATION AND PROCUREMENT Song-Yi Kim , Korea
625	VIABILITY EVALUATION OF DCD KIDNEY DURING REWARMING MACHINE PERFUSION Hiromichi Obara , Japan
626	SUCCESSFUL EX VIVO LUNG PERFUSION; DON`T MAKE ANY MISTAKE! Shadi Shafaghi, Iran (Islamic Republic of)
627	HYPOTHERMIC MACHINE PERFUSION OF KIDNEYS FROM LIVING DONORS Jacques Malaise , Canada
628	KIDNEY TRANSPLANTATION FROM DONORS AFTER CARDIAC DEATH DONORS WITH ONE WARM ISCHEMIC TIME: 5-YEARS OUTCOMES Oleg N. Reznik, Russian Federation

11:00-12:30	Oral Presentation: Public Policy Grand Ballroom III
	Chairs: Richard Hasz, United States and Yeong Hoon Kim, Korea
630	IMPACT OF THE DOHA MODEL OF ORGAN DONATION AND TRANSPLANTATION: FIVE YEARS AFTER IMPLEMENTATION OF THE DOHA DONATION ACCORD Riadh Fadhil , Qatar
631	THE OUTCOMES MODEL: CO-OPERATION BETWEEN BUSINESS LEADERS, TRANSPLANT SPECIALISTS AND THE COMMUNITY TO LEAD CHANGES IN THE ORGAN DONATION SYSTEM IN AUSTRALIA Maria P. Gomez, Australia
632	THE DEVELOPMENT AND MANAGEMENT OF CHINA ORGAN PROCUREMENT ORGANIZATION ALLIANCE Xiaoli Fan, People's Republic of China
633	IMPACT OF INTRODUCING FULL-TIME, IN-HOUSE COORDINATORS ON REFERRAL AND ORGAN DONATION RATES IN RIO DE JANEIRO PUBLIC HOSPITALS: A HEALTHCARE INNOVATION PRACTICE Rodrigo Al Sarlo, Brazil
634	KNOWLEDGE, ATTITUDES, AND BELIEFS TOWARD ORGAN DONATION AMONG SOCIAL MEDIA USERS Abeer Waleed Alfardan, Saudi Arabia
635	REGISTRATION FOR DECEASED ORGAN AND TISSUE DONATION AMONGST NEW CANADIANS: A POPULATION-BASED STUDY Alvin Li , Canada
636	ATTITUDES AND BELIEFS ABOUT DECEASED ORGAN DONATION IN ARABIC-SPEAKING COMMUNITIES IN AUSTRALIA: A FOCUS GROUP STUDY Angelique F. Ralph , Australia
637	A SYSTEMATIC TRANSLATION PROCESS FOR CROSS-CULTURAL ADAPTATION OF THE INSTRUMENT: ATTITUDES TOWARDS ORGAN DONOR ADVOCACY SCALE (ATODAS) Anne Floden, Sweden
638	THE WORKING TOGETHER ALLIANCE (WTA): AN INTERNATIONAL TOOL TO DESIGN A COMMON ACTION PLAN TO MAXIMIZE THE IMPACT OF THE INITIATIVES RELATED ORGAN DONATION AND TRANSPLANTATION Chloë Ballesté, Spain

11:00-12:30	Oral Presentation: Late Breaking	Studio I-II
	Chairs: Susan Gunderson, United States and Sungjoo Kim, Korea	
640	RESULTS OF DELAYED GRAFT FUNCTION(DGF) IN KIDNEY TRANSPLANT IN ARGENTINA Liliana E. Bisigniano , Argentina	
641	IN SITU AORTIC FLUSH WITH LACTATED RINGER'S SOLUTION DURING ADULT DONATION AFTER BRAIN DEATH ORGAN PROCUREMENT PROVIDES SIMILAR OUTCOMES AND SIGNIFICANTLY DECREASES COSTS IN ADULT LIVER AND RENAL TRANSPLANTATION COMPARED TO UNIVERSITY OF WISCONSIN SOLUTION OR HTK Steven M. Rudich , United States	
642	EUROPEAN MEDITERRANEAN POSTGRADUATE PROGRAM ON ORGAN DONATION AND TRANSPLANTATION (EMPODAT) Chloë Ballesté, Spain	
644	'IT'S ABOUT TIME OUR COMMUNITY STARTED TO TALK ABOUT ORGAN DONATION' RAISING AWARENESS OF ORGAN DONATION WITHIN THE PAKISTANI/INDIAN COMMUNITY Angela L. Ditchfield, United Kingdom	
646	KIDNEY PAIRED DONATION AND ITS IMPLICATION ON RECIPIENTS HAVING COMPLICATED IMMUNOLOGICAL BARRIERS; EXPERIENCE OF THREE WAY KIDNEY PAIRED DONATION IN A SINGLE CENTER Dong Kyu Oh, Korea	
647	ORGAN TRANSPLANTATION IN THE GULF COOPERATION COUNCIL (GCC) COUNTRIES Faissal A.M. Shaheen, Saudi Arabia	
648	COMPUTATIONAL PREDICTION OF ACUTE REJECTION IN KIDNEY TRANSPLA RECIPIENTS USING A MULTICENTER COHORT Kyung Don Yoo , Korea	NT
12:30-13:00	Lunch Break	Level 3F
13:00-14:10	Debate: Controversies in Heart Transplantation from DCD	Grand Ballroom
	Chair: Francis L. Delmonico, United States	
650	REPORT OF THE CASES OF HEART TRANSPLANTATION FROM DCD IN AUSTRALIA Peter S. MacDonald , Australia	
651	REPORT OF THE CASES OF HEART TRANSPLANTATION IN US David N. Campbell , United States	
652	SCIENTIFIC BACKGROUND OF DEATH DETERMINATION IN DCD Stephen Beed , Canada	
653	TERMINOLOGY AROUND DEATH AND DONOR FAMILIES James A. Hynds, United States	

14:10-14:30	Coffee Break	Park Ballroom Foyer Area
14:30-16:00	Oral Presentation: Public Campaigns	Grand Ballroom
	Chairs: Dominique E. Martin, Australia and Hyoung Tae Kim, Korea	
660	A DEMOGRAPHIC PROFILE OF THOSE WHO SKIP THE VITAL TALK AFTER TAK ORGAN DONATION PLEDGE Sunil Shroff , India	(ING AN
661	ATTITUDE AND AWARENESS TOWARDS ORGAN DONATION IN WESTERN INI Manish R. Balwani , India	DIA
662	SUSTAINABILITY OF ETPOD PROGRAM (EUROPEAN TRAINING PROGRAM O ORGAN DONATION) IN POLAND; THE IMPACT ON DONATION INDICATORS Jarosław Czerwiński, Poland	,N
663	EFFECTIVE PUBLIC EDUCATION CAMPAIGNS PROMOTING STATE DONOR REINCREASE DONOR DESIGNATIONS AND ACTUAL ORGAN DONATION John D. Green , United States	EGISTRIES
664	PUBLIC EDUCATION USING VOTING SYSTEM, A BETTER METHOD TO DELIVE INFORMATION ABOUT ORGAN DONATION AND TRANSPLANTATION TO THE Won-Hyun Cho , Korea	
665	SEUSA PROGRAM: A SUCESFULL MODEL TO DEVELOP A DONATION SYSTEM THE TRINIDAD AND TOBAGOEXPERIENCE Chloë Ballesté , SPAIN	v 1.
666	PUBLIC KNOWLEDGE AND ATTITUDES TOWARDS ORGAN DONATION AND TRANSPLANTATION IN SRI LANKA: A PILOT STUDY Dominique E. Martin , Australia	
667	THE INSUFFICIENT INFORMATION ABOUT THE DONATION TO THE GENERAL PUBLIC AND THE EXCESSIVE PRUDENCES OF THE DOCTORS IN THE EMERGE INSTITUTES HAMPER THE DEVELOPMENT OF THE TRANSPLANTATION MEDI Shun-ichi Yoshikai , Japan	ENCY
668	A STUDY ON THE RECOGNITION OF INDEPENDENT ORGAN PROCUREMENT ORGANIZATION (IOPO) AND ITS ROLES IN KOREA Kyung Sook Jang , Korea	

14:30-16:00	Oral Presentation: Donor Management
	Chairs: Thomas Nakagawa, United States and Jae Myeong Lee, Korea
670	EXTENDED CRITERIA LUNG DONATION- ITS NOT WHAT YOU'VE GOT BUT WHAT YOU DO WITH IT Jamie Hobson, Australia
671	MANAGEMENT OF DECEASED DONORS AND OUTCOMES OF DECEASED DONOR KIDNEY TRANSPLANTATION Seong Sik Kang, Korea
672	LONG-TERM COSMETIC OUTCOMES OF WOUND FOLLOWING THE DIFFERENT MINIMALLY INVASIVE INCISIONS FOR LIVING DONOR HEPATECTOMY IN LIVER TRANSPLANTATION Kyung Ae Kim, Korea
674	ORGAN DONATION FROM DONORS WITH SYSTEMIC INFECTION: A SINGLE CENTER EXPERIENCE Xiaopeng Yuan, People's Republic of China
676	PRE-TRANSPLANT LIVE DONOR EVALUATION PROTOCOL FOR LIVER TRANSPLANTATION AT A SINGLE MAJOR CENTER Sanghee Song, Korea
677	OUTCOME OF SPLIT-LIVER TRANSPLANTATION IN KOREAN: ANALYSIS OF THE KONOS DATA BASE Sanghee Song, Korea
678	RISK FACTOR FOR INITIAL POOR GRAFT FUNCTION IN ORTHOTOPIC LIVER TRANSPLANT Sung Won Jung , Korea
14:30–16:00	Oral Presentation: Living Donation
	Chairs: Shin Hwang, Korea and Adam W. Bingaman, United States
680	"EVERYONE'S GOT THEIR OWN THRESHOLD" NEPHROLOGISTS' PERSPECTIVES ON PATIENT ELIGIBILITY AND ACCESS TO LIVING KIDNEY DONOR TRANSPLANTATION Camilla S. Hanson, Australia
681	ADVANCES OF DONOR OPERATION IN LIVING DONOR LIVER TRANSPLANTATION FROM OVER 1,000 CASES AT A SINGLE INSTITUTION Kyung-Suk Suh , Korea
682	FACTORS THAT ARE ASSOCIATED WITH POTENTIAL LIVING DONORS WHO DO NOT COMPLETE THE EVALUATION PROCESS Joyce A. Trompeta, United States

16:00-16:30	Coffee Break	Park Ballroom Foyer Area
694	PERSPECTIVE FROM MYANMAR Htar Kyi H. Swe , Myanmar	
693	PERSPECTIVE FROM MONGOLIA Pandaan Batchuluun, Mongolia	
692	PERSPECTIVE FROM MALAYSIA Fadhilah Zowyah Lela Yasmin Mansor, Malaysia	
691	PERSPECTIVE FROM PAKISTAN S.A. Anwar Naqvi, Pakistan	
690	PERSPECTIVE FROM VIETNAM Thi Ngoc Thu Du, Vietnam	
689	Chair: Francis L. Delmonico, United States PERSPECTIVE FROM BANGLADESH Mir M. Rahman, Bangladesh	
14:30-16:00	Round-Table: Bangladesh, Malaysia, Mongolia, Myanmar, Pakistan and Vietnam	Studio I-II
688	AUSTRALIAN KIDNEY EXCHANGE (AKX) DONOR KIDNEYS TRAVEL IN STYLE Richard D. M. Allen , Australia	
687	CAUSES OF EXCLUSION DURING LIVING DONOR EVALUATION Ahram Han , Korea	
686	PRE DONATION FACTORS AFFECTING POST DONATION ALBUMIN EXCRETIC IN LIVING KIDNEY DONORS Hatem Amer , United States	N
685	OUTCOMES OF SECOND KIDNEY TRANSPLANTATION COMPARED PRIMARY TRANSPLANTATION Jae Geun Lee, Korea	
684	PSYCHOSOCIAL IMPACT OF DONATION PROCESS: EVALUATION OF LIVING KIDNEY DONOR SATISFACTION Ana Teresa T. Menjivar , Spain	
683	PERSPECTIVES OF DONORS AND RECIPIENTS ON THE IMPACT OF LIVING KIDNEY DONATION ON DONOR-RECIPIENT RELATIONSHIPS: THEMATIC SYNTHESIS OF QUALITATIVE STUDIES Angelique F. Ralph, Australia	

16:30–18:00	Concurrent Symposium: Challenging Aspects in the Work of a Coordinator	Grand Ballroom I
	Chairs: Bok Nyeo Kim, Korea and Marti Manyalich, Spain	
700	DIFFICULTIES IN GETTING ADEQUATE PAST MEDICAL INFORMATION Philippe Morel , Switzerland	
701	DIFFICULTIES IN FAMILY APPROACH Meg M. Rogers, United States	
702	DIFFICULTIES IN DONOR ASSESSMENT Günter Kirste , Germany	
703	ORGANISATIONAL DIFFICULTIES Kevin O'Connor, United States	
16:30-18:00	Concurrent Symposium: Promoting Organ Donation	Grand Ballroom II
	Chairs: Kimberly P Young, Canada and Chul Woo Yang, Korea	
710	APPROACH TO PROFESSIONALS Susan Gunderson, United States	
711	HOW TO TEACH CHILDREN IN SCHOOL Kimberly P. Young, Canada	
712	COMMUNITY PROMOTION Susan Mau Larson, United States	
713	APPROACH TO POLICY MAKERS Jeremy R. Chapman, Australia	
16:30–18:00	Concurrent Symposium: Tissue Donation	Grand Ballroom III
	Chairs: Sungjoo Kim, Korea and Howard M. Nathan, United States	
720	PITFALLS IN FAMILY APPROACH John P. Clarke, United States	
721	TISSUE RECOVERY SURGERY Gerald Brandacher, United States	
722	HOSPITAL BASED OR INDEPENDENT FACILITY BASED Howard M. Nathan, United States	
723	REQUIREMENT VS SUPPLY: UNMET NEEDS Faissal A.M. Shaheen, Saudi Arabia	

18:00-19:00	Plenary: Closing Ceremony	Grand Ballroom I-II-III
	Chair: Jongwon Ha, Korea	
731	SUMMARY OF ROUNDTABLE DISCUSSION 1 & 2 Francis L. Delmonico, United States	
732	MEETING WRAP-UP / REPORT ON ISODP ACTIVITIES Kimberly P. Young, Canada	
733	PRESENTATION FOR GENEVA 2017 Philippe Morel, Switzerland	
734	CLOSING ADDRESS Jongwon Ha, Korea	

NOTES



WORLD DAY OF ORGAN DONATION AND TRANSPLANTATION (WDODT)

The WDODT will be held to let Koreans know the importance of organ donation and to respect organ donors.

FORUM

15:00-17:30 • Conrad Hotel - Studio I-II-III, Level 6F

The alternative to improve brain death organ donation, DCD (Donation after Circulatory Death)

EVENTS

Ceremony

10:30-11:00 • Yeouido Park (Across from the Conrad Hotel)

Hold the green balloon performance

Walking Event

11:00-12:00 • Yeouido Park

Walking together to spread the positive organ donation culture in Korea

Lunch

12:00-13:00 • Yeouido Park

Hope Concert

13:00-15:00 • Yeouido Park

With K-pop groups, Indi-band teams and The Voice of Life Choir

EXHIBITION

10:00-15:00 • Yeouido Park

Booth Activities with NGOs and mini-events

SOCIAL ACTIVITIES

OPENING CEREMONY

Date: Saturday, October 17th, 2015

Time: 18:30-19:30

Place: Grand Ballroom 3F, Conrad Hotel

Cost: Free of charge (included in registration fee)

All registered participants are cordially invited to join us and celebrate the official opening on the ISODP2015 Congress.

The KODA coordinators welcome delegates with traditional Korean dance and the KODA choir, The Voice of Life, which is made up of organ donors' families, recipients and medical professionals (doctor and coordinator). The choir will sing a song for donation and transplantation, providing delegates with an inspiring and unforgettable memory of their time in Korea.

WELCOME RECEPTION

Date: Saturday, October 17th, 2015

Time: 19:30-21:00

Place: 5F Lobby and Exhibition Area (Park Ballroom)
Cost: Free of charge (included in registration fee)

All registrants are very welcome and a light buffet and a drink will be provided.



SOCIAL ACTIVITIES

CONGRESS DINNER

Date: Monday, October 19th, 2015

Time: 19:30-21:30

Place: Grand Ballroom 3F, Conrad Hotel

Cost: \$50 USD

Enjoy the climax of ISODP2015 with an excellent dinner and exciting performance, yet another opportunity to mingle with colleagues in pleasant surroundings.

Tickets are available for \$50 USD and will be required onsite. Onsite purchase is available until Sunday, October 18th before 18:00.



CLOSING CEREMONY

Date: Tuesday, October 20th, 2015

Time: 18:00-19:00

Place: Grand Ballroom 3F, Conrad Hotel

Cost: Free of charge (included in registration fee for all attendees)

Take the opportunity to say farewell to friends and colleagues, to celebrate the success of

the congress and to cherish the memories from ISODP2015

EXHIBITION INFORMATION

EXHIBITION HOURS

•	Saturday, October 17	18:00-21:00
•	Sunday, October 18	08:00-19:00
•	Monday, October 19	08:00-19:00
•	Tuesday, October 20	08:00-19:00

LIST OF EXHIBITORS (BY BOOTH NUMBER)

LEVEL 3F


- A The Transplantation Society
- B ISODP 2017
- C Korea Organ Donation Agency (KODA)
- D Vitallink

LEVEL 5F


- 1-4 Chong Kun Dang Pharm.
- 5-7 Roche Korea Co., Ltd
- 8 Transplant Connect
- 9 Mitsubishi Tanabe Pharma Corporation
- 10-12 Novartis Korea
- 13-16 Astellas Pharma Korea
- 17 SK Plasma
- 18 Gift of Life Institute
- **19** TPM
- 20 Bridge to Life
- 21-23 Green Cross
- 24-25 Gilead Sciences
- 26 Organ Recovery System
- 27-29 Sanofi-Aventis Korea Co., Ltd

EXHIBITION INFORMATION

3F



5F



PLATINUM SPONSOR

Astellas Pharma Korea

BOOTH 13-16

3F. Kumha Bldg., #41-2 Chungdam-dong, Gangnam-gu, Seoul 135-766 Korea



www.astellas.com

Astellas Pharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network. It was founded on April 1st, 2005, through a merger between Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd., using 100% Japanese funding and dedicated to the goal of continued increase in company value.

Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination common in women, overactive bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Prograf and Advagraf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.

Astellas Pharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Prograf, Advagraf, Harnal, Vesicare and Protopic Ointment. It is also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. Astellas Pharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and those seeking better health, by establishing its Global Category Leader business model.

GOLD SPONSOR

Chong Kun Dang Pharm.

BOOTH 1-4

368, 3-ga, Chungjeong-ro Seodaemun-gu, Seoul 120-756 Korea

www.ckdpharm.com



Since its founding, for the past 70 years Chong Kun Dang has only made pharmacies based on the dignity of human lives. Chong Kun Dang has set up implementation of healthy society without diseases as the company ideology while making better pharmacy.

This is the value that will never change as long as Chong Kun Dang exists as a pharmacy company.

SILVER SPONSORS

Green Cross

BOOTH 21-23

107, Ihyeon-ro 30beon-gil, Giheung-gu Yongin-si, Gyeonggi-do Korea



www.greencross.com

Having spearheaded the biotechnology industry in Korea for the last half century, Green Cross is now evolving into 'a global leader in healthcare industry' for a bright future for everyone.

For this, Green Gross promises it will put into practice its values: care, compassion, fairness, integrity and respect for all humanity. These are the values embodied by Green Cross on the basis of the spirit of creativity and challenge.

Novartis Korea

BOOTH 10-12

84-11, Namdaemunno 5-ga Jung-gu, Seoul Korea



www.novartis.com

Novartis AG, headquartered in Basel, Switzerland, is a leading global innovation-driven pharmaceutical company which is committed to discover and develop innovative drugs to cure diseases, to ease suffering and to enhance the quality of life through its more than 140-year history. Today, Novartis is one of the fastest growing global pharmaceutical companies, ranking the second largest in the world. Novartis Group companies employ about 100,000 people and operate in over 140 countries. Novartis Korea is an affiliate of Novartis AG.

SILVER SPONSORS

Roche Korea Co., Ltd

17th Fl. GT Tower, 1317-23 Seocho-dong, Seocho-gu, Seoul 137-070 Korea

www.roche.com





Roche Korea is a Korean subsidiary of F. Hoffmann-La Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, headquartered in Basel, Switzerland.

Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism, CNS and Transplantation. Roche's transplant treatments are designed to support the long-term survival of the transplanted organ. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicine and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

Roche employs more than 80,000 people and sells its products in more than 150 countries. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chuqai Pharmaceutical, Japan.

Sanofi-aventis Korea Co., Ltd

235, Banpo-daero Seocho-gu, Seoul Korea

www.sanofi.com

BOOTH 27-29



Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

EXHIBITORS

Bridge to Life

BOOTH 20

128 Suber Rd. Columbia, SC 29210 USA

www.bridgetolifesolutions.com



Bridge to Life supplies organ preservation solutions under the Belzer UW® trademark – including a new 500 mL size of our cold storage solution. We also offer a line of high-flow tubing sets and cannulas, designed for optimal performance in the OR setting. Please stop by our booth to learn more.

Gift of Life Institute

BOOTH 18

401 N. 3rd Street Philadelphia, PA 19123 USA

www.giftoflifeinstitute.org



Gift of Life Institute is an international training center for donation professionals offering comprehensive, interdisciplinary resources for skills-based learning, continuing education, collaborative research, and consulting services.

EXHIBITORS

Gilead Science Korea

BOOTH 24-25

67, Suha-dong, Jung-guro Jung-guro, Seoul Korea



www.gileadkorea.co.kr

Advancing Therapeutics, Improving Lives.

Gilead Sciences is a global biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

With each new discovery and investigational drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world. Gilead's therapeutic areas of focus include HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions.

Since its founding in Foster City, California in 1987, Gilead has become a leading biopharmaceutical company with a portfolio of 19 marketed products, a growing pipeline of investigational drugs and approximately 7,000 employees in offices across six continents.

Established in 2011, Gilead's office in Seoul contributes to our medical, regulatory, marketing and commercial initiatives, which support our growing global business.

ISODP 2017 BOOTH B

The next edition of the ISODP Congress will be held under the auspices of Swisstransplant in the beautiful city of Geneva, Switzerland from September 6–9, 2017.

www.isodp.org

EXHIBITORS

Korea Organ Donation Agency (KODA)

BOOTH C

16, Nonhyeon-ro 136-gil Gangnam-gu, Seoul Korea

www.koda1458.kr



KODA was designated as the organ procurement organization of Korea by the Ministry of Health and Welfare according to the Transplant Act.

When a case of presumed brain death takes place, we are informed by the hospital about the presumed brain dead patients and carry out tasks related to brain death organ donation. KODA is there where lives are linked.

Mitsubishi Tanabe Pharma Korea

BOOTH 9

2806, Nambusunhwan-ro Gangnam-gu, Seoul Korea



www.mt-pharma-korea.com

Mitsubishi Tanabe Pharma Korea is the Korean subsidiary of the Mitsubishi Tanabe Pharma Group in Japan.

Mitsubishi Tanabe Pharma's philosophy states that "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals." Mitsubishi Tanabe Pharma is striving to become a research-driven pharmaceutical company that works with a sense of speed and is the first to deliver original value to patients and health care professionals.

EXHIBITORS

Organ Recovery System

BOOTH 26

One Pierce Place, Suite 475W Itasca, IL 60143 USA



www.organ-recovery.com

Organ Recovery Systems, the global market-leading provider of organ preservation products and services, is committed to helping clinicians improve outcomes, supporting 193 transplant programs in 28 countries with the LifePort® Kidney Transporter. The LifePort Liver Transporter, featuring the same proven technology platform, is undergoing regulatory review in the US and EU. Organ Recovery Systems provide SPS-1® (UW solution) and KPS-1® (UW machine perfusion solution), leading the way in delivering the gold-standard in organ preservation solutions.

SK Plasma BOOTH 17

310, Pangyo-ro, Bundang-gu Seongnam-si, Gyeonggi-do Korea



www.skplasma.com

SK Chemicals have been transferred to a newly established subsidiary, SK Plasma. SK Plasma was established in order to focus solely on the plasma business. We expect that this change will enable us to expand our business worldwide.

Transplant Connect

2701 Ocean Park Blvd., Suite 222 Santa Monica, CA 90405 USA



www.transplantconnect.com

From San Francisco to Sydney, Transplant Connect is the world's leading provider of electronic medical record systems for organ, tissue and ocular donation and transplantation. Our secure, web-based iTransplant Enterprise System is relied upon every day by many thousands of medical professionals around the globe to expedite and increase donation and transplantation and to reduce errors and increase operational efficiency. Contact us for a no-cost demonstration of our iTransplant Enterprise System to learn how your donation agency or transplant center can improve your results with our state-of-the-art clinical and operational software.

EXHIBITORS

The Transplantation Society (TTS)

BOOTH A

505 boul. René-Lévesque Ouest, Suite 1401 Montreal, QC H2Z 1Y7 Canada



www.tts.org

The Transplantation Society, established in 1966, serves as the principle international forum for the advancement of both basic and clinical transplantation science throughout the world. TTS provides the focus for global leadership in transplantation science and clinical practice, scientific communication, education and guidance on ethical practices.

TTS is also pleased to have a distinguished team of Sections affiliated with the society: the Cell Transplant Society (CTS), the International Hand and Composite Tissue Allotransplantation Society (IHCTAS), the International Pediatric Transplant Association (IPITA), the International Society for Organ Donation and Procurement (ISODP), the International Xenotransplantation Association (IXA), the Intestinal Rehabilitation and Transplant Association (IRTA), and Transplant Infectious Disease (TID). Please visit our booth in the foyer area to get information on membership, find out more about our Sections and get information on our future meetings.

Transplant Procurement Management (TPM)

BOOTH 19

BaldiriReixac 4-8, Torre 1, Planta 8 Barcelona 08028 Spain





www.tpm.org

Transplant Procurement Management (TPM) is a strategic international system approach to fight organ and tissue shortage. It was launched in 1991 under the auspices of the University of Barcelona as a specialized professional training project.

TPM has collaborated in developing the Spanish Model by implementing face-to-face, online and blended training programs at different professional levels. Its main goal is to increase the quantity, quality and effectiveness of organ and tissue donation for transplantation, by training and advising health care professionals in the organ donation process. Moreover, TPM alongside with DTI Foundation suggests strategies on how to develop successful organ procurement programs.

EXHIBITORS

Vitallink

105 Detached Building of Seoul National University 199-1 Doungsung-dong, Jongno-gu, Seoul Korea

www.vitallink.or.kr



Vitallink is a compound word combining "vital" and "link", which means linking donor's vitality to the recipient by organ donation. As shown in the name of this organization, Vitallink was founded in 2009 by medical professionals working in the field of transplantation and organ procurement to achieve a global standard of organ donation culture and to publish educational and promotional materials to support other NGOs' activity in Korea. Developing policies about organ donation and transplantation and proposing policies to the government are other important roles of Vitallink. With other NGOs working in the field of organ donation activation, Vitallink established the "Korean Donate Life Network" and formed a coalition between organizations for a better and effective organ donation campaign. Vitallink held the Korean Transplant Games to support transplant patients and their rehabilitation and health on October 25-26, 2014. Vitallink also held the 4th Vitallink International Workshop to help Mongolia and Myanmar create systems for the self-sufficiency of organ donation on January 28, 2015. Through the Vitallink International Workshop we provided the chance to discuss and share the most appropriate methods to activate organ donation and transplantation together and to define the practical application and implementation of organ donation and transplantation according to each country's circumstances.

DISCOVER SEOUL

HISTORY

Located at the heart of the Korean Peninsula, Seoul has been an important strategic point throughout the centuries for defensive and economic reasons, from one kingdom to the next. The three kingdoms of Baekje, Goguryeo, and Silla (BCE 57–CE 688) all fought over the area that is now Korea's capital. Indeed, whichever kingdom claimed Seoul became the dominant power. The Joseon Dynasty (1396–1910) declared Seoul its capital, a role that Seoul still plays to this day.

TOUR INFORMATION

Adults

Children 13-18

Children 2–12

Traditional Culture Tour

Ticket booth located in front of Doosan Tower, Dongdaemun Phone: 02-1544-4239 www.seoultrolley.co.kr/main.html

15.000 won

10.000 won

10,000 won

Seoul City Courses

Ticket booth located at Gwanghwamun, next to Koreana Hotel
Phone: 02-777-6090 www.seoulcitybus.com

· City · Royal Palaces

12,000 won 10,000 won 10,000 won

Seoul Panorama

15,000 won 10,000 won 10,000 won

Nighttime I (Single-decker)

6,000 won 4,000 won 4,000 won

• Nighttime II (Double-decker)

12,000 won 7,000 won 4,000 won

Gangnam City Tour

Gwangnam Tourist Information Center

Phone: 02-3423-5542 www.gangnamtour.go.kr

12,000 won 12,000 won 6,000 won (trollybus)

EMERGENCY NUMBERS

Police Department: Tel. 112

Fire Department/Ambulance: Tel. 119 Tourist Information Center: Tel. 1330



HOTEL AND CITY MAP



TRANSPORTATION

CONRAD HOTEL

23-1 Yeouido-dong Yeongdeungpo-gu, Seoul, 150-945, South Korea

Tel. +82-2-6137-7000 Fax. +82-2-6137-7001

Conrad Hotel --> Incheon International Airport

1) Limousine Bus

Bus Number	Bus Stops	Frequency	Travel Time	Fare
6030	IFC Seoul Conrad Hotel	Every 20~30 Min.	~50 Min.	KRW 15,000
6702	Yeouido Trans. Center	Every 20~30 Min.	60~70 Min	KRW 16,000

2) Subway

- Take Line No.5 (Purple) train bound for Yeouido station
- · Get off at Gongdeok station
- Transfer to commuter train (Airport Line) Bound for Incheon Airport
- Get off at Incheon Airport Station

Category	Fare	Time	Frequency	Operation Hours
Commuter Train	KRW 4,050	85 minutes	Every 12 minutes	5:24 ~ 23:42

3) Taxi

- Standard / International Taxi KRW 70,000
- Deluxe / Jumbo Taxi KRW 90,000

Conrad Hotel -> Gimpo Airport

1) Bus

Bus Number	Bus Stops	Frequency	Travel Time	Fare
300	Seoul Yoido Exhibiton Center	Every 20~30 min.	~60min.	KRW 1,500

2) Subway

- · Take Line No.9 (Gold) train bound for Yeouido station
- Get off at Gimpo airport station

Category	Fare	Time	Frequency	Operation Hours
Commuter Train	KRW 4,050	85 minutes	Every 12 minutes	5:24 ~ 23:42

3) Taxi

- Standard / International Taxi KRW 20,000
- Deluxe / Jumbo Taxi KRW 30,000

TRANSPORTATION





Target exposure


ENGINEERED FOR A LIFETIME OF CONSISTENT CONTROL

- Variability in calcineurin inhibitor exposure can result in reduced renal function or graft life¹⁻³
- Higher intrapatient variability in PROGRAF® (tacrolimus) exposure was associated with an increased risk of graft failure beyond 12 months post-transplant (P=0.003)⁴
- Prolonged-release ADVAGRAF has been engineered to deliver a lifetime of consistent, predictable control of tacrolimus exposure⁵

References: 1. Waiser J, Slowinski T, Brinker-Paschke A, et al. Nephrol Dial Transplant. 2002;17(7):1310-1317. 2. Kahan BD, Welsh M, Urbauer DL, et al. J Am Soc Nephrol. 2000;11(6):1122-1131. 3. Stoves J. Newstead CG. Transplantation. 2002;74(12):1794-1797. 4. Borra LC, Roodnat JI, Kal JA, et J. Nephrol Dial Transplant. 2010;25(8):2757-2763. 5. European Medicines Agency. European public assessment report (EPAR): Advagraf: scientific discussion.



TAKE CONTROL. FOR LIFE.



A proven record with adjunctive therapies supports the fundamental role of Prograf* in liver, kidney and heart transplantation. Experience has also shown that Prograf* is an ideal immunosuppressant for steroid-sparing or withdrawal therapies.

Most importantly, for each and every patient, all this Prograf® experience adds to their life story.







- ✓ 0.25mg strength launched for the first time in the world
- ✓ Patented using newly developed concept of Solid Dispersion technology
- ✓ Biological equivalence proved through clinical trials
- Efficacy and safety proved by Phase IV clinical trials to patients of kidney or liver transplantation

Participation hospitals in clinical trials:

Asan Medical Center, Chonbuk National University Hospital, Chonnam National University Hospital, Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Severance Hospital, Hallym University Medical Center, Hanyang University Medical Center, Keimyung University Dongsan Medical Center(listed in alphabetical order)






CellCept® Trust What You Know

CellCept (mycophenolate mofetil) CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants, CellCept should be used concomitantly with cyclosporine and corticosteroids. Dosage I. Renal Transplantation "Adultis: A dose of 1 g administered orally or intravenously twice a day (daily dose of 2 g) is recommended for use in renal transplant patients. Although a dose of 1.5 g administered twice daily (daily dose of 3 g) was used in clinical trials and was shown to be safe and effective, no efficacy advantage could be established for renal transplant patients. See that the part of the part available for cardiac or hepatic transplant patients with severe chronic renal impairment. (3) Elderly patients (65 years), particularly those who are receiving CellCept as part of a combination immunosuppressive regimen, may be at increased risk of certain infections and possibly gastrointestinal hemorrhage and pulmonary edema, compared to younger individuals (4)If neutropenia develops (ANC < 1.3 x 103/), dosing with CellCept should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately. 5. The clinical impact of reduced MPA exposure on organ rejection has with CeliCept should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately. 5. The clinical impact of reduced MPA exposure on organ rejection has not been established in transplant patients receiving PPIs and CeliCept. 1. UMRAINING. (I) Used uring pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning.(2) Immunosuppression may lead to increased susceptibility to infection and possible development of hymphoma. Only physicians expensions plant in the productive pr remainder of whether and shake the closed bottle will for about 1 minutes. Remove the child-resistant cap and push bottle adapter into neck of bottle. 6. Close bottle with child-resistant cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child-resistant status of the cap.







모글로부린주사 (인체용선세포로 면역시킨 레빗드의 항용선 면역 글로부린

희귀/전문의약품

대통 및 1801 Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale on the 18-18 of Principles (Fig. 2011) Lad S cale of Principles (Fig. 20

자세한 사항은 제품설명서 또는 회사 홈페이지(www.sanoti.co.kr)를 참조해주십시



enteric-coated mycophenolate sodium

Lifelong commitment

To you. To your patients. To a successful transplant.

노바티스는 새로운 삶에 대한 약속입니다



Full Strength Protection, Start with Optimal MPA dosing Myfortic® Helps to Maintain Recommended Dosing 1-6



Antithrombin-III inj.



[Indications]

- Prophylaxis and treatment of thromboembolism complications caused by congenital antithrombin-III deficiency
- 2. Prevention and treatment of acquired antithrombin-III deficiency

[Dosage & Administration]

- 1. Dosage
 - 1) Donage

Administer Antithrombin-III at 1,000~1,500 I.U. per day based on the degree of antithrombin-III consumption

) Treatment

Administer Antithrombin-III at 1,000-2,000 LU, as initial dose or at 2,000-3,000 LU, per day as maintenance dose; carry out split-dose administration by 500 LU, at 4 ~ 6 hour intervals or continuous intravenous drip.

3) Treatment Period

Administer Antithrombin-III until the antithrombin-III plasma level becomes normal and all

symptoms disappear. 2. Administration

Reconstitute the freeze-dried powder in 10 mL of sterile water for injection and administer it by slow intravenous injection or drip infusion. For drip infusion, 5% human albumin solution is the most appropriate diluent; Ringer's lactate solution, normal saline solution, or glucose injection 5% may be used when diluted at up to 1:10.

[Package]

Antithrombin-III (human) 500 I.U./Vial x 1, Sterile water for injection 10 mL/Vial x 1

Consumer consulting center ☎+82-31-260-9300





One Stop Solution

Setting New Standards Through Innovation

NOTES

PRESENTER INDEX

Adair-Kriz, Michael	445	Clarke, John P	447, 505, 720
Aikawa, Atsushi	458	Coco, Tina A	400
Akashi, Yumi563 (see page 39), 579	Czerwiński, Jarosław	266, 352, 492, 662
Al Mousawi, Mustafa S. A	302, 512	Daly, Theresa A	443, 444, 493
Alfardan , Abeer Waleed	634	Delmonico, Francis L	133, 731
Allen, Richard D. M	514, 688	Dhitavat, Visist	542
Al Sebayel, Mohammed Ibrahim	1616	Dias da Curz, Luiz Gustavo	Torres490, 610
Amer, Hatem	686	Ditchfield, Angela L	644
Ashikari, Juntaro	356	Doskali, Marlen	516
Baek, Sunmi	570	Du, Thi Ngoc Thu	690
Ballesté, Chloë311, 314, 5	565, 638, 642, 665	Fadhil, Riadh	630
Balwani, Manish R	661	Fan, Xiaoli	632
Bang, Jun Bae	372	Ferreira, Joseph	558
Batchuluun, Pandaan	693	Floden, Anne	483, 484, 637
Beaulieu, Louis	210	Franzén, Carin B	375
Beed, Stephen	410, 413, 652	Fraser, Campbell	261
Bingaman, Adam W	521	Fukushima, Norihide	533
Bisigniano, Liliana E	435, 640	Ghobadi, Omid	510, 511
Bohatyrewicz, Romuald	282	Gill, John S	340, 602
Bollen, Jan	263	Gomez, Maria P	433, 631
Bos, Michael A	220	Gordon, Chad	233
Brandacher, Gerald	231, 721	Green, John D	441, 611, 663
Brehm, Kerstin	111	Gunderson, Susan	201, 710
Brubaker, Scott A	123, 423	Gupta, Preeti	262
Callender, Clive O	614	Ha, Jongwon	131, 734
Campbell, David N	651	Han, Ahram	687
Cebotari, Serghei	321	Hanson, Camilla S	295, 680
Chapman, Jeremy R	221, 713	Hantson, Philippe	253
Cho, Hong Rae	377	Hasz, Richard	438, 481, 506
Cho, Jai Young	368	Herrera, George A	122, 422
Cho, Won-Hyun	200, 553, 664	Herson, Marisa R	421
Cho, Yong W	362	Hobson, Jamie	670
Choi, Byung Hyun	382	Holloway, Kent	532
Choi, Chanjoong	300	Hong, Jong Won	517
Chong, Hye Jin	360	Hong, Jungsu	461
Clark, Suzi M	612	Hong, Seungheui	380
Clarke, Caitlin	468, 480	Hussein, Kamal H	464

PRESENTER INDEX

Hynds, James A	653	Lee, Won Jung	366
Ison, Michael G	100, 250	Lee, Young Joo	369
Jang, Hye Yeon	557	Lee, Yunmi	384
Jang, Kyung Sook	668	Leichtman, Alan B	332
Jung, Sung Won	678	Lewis, Virginia	450, 485, 486
Jushinskis, Janis	500	Li, Alvin	635
Kang, Jeong Hee	374	Li, Li	545
Kang, Seong Sik	671	Lim, Hye Jin	387
Keith, Simon S	313, 617	Macdonald, Peter S	650
Kim, Bok Nyeo	371	Malaise, Jacques	466, 627
Kim, Gahee	291	Mansor, Fadhilah Zowyah Lela Ya	ısmin692
Kim, Hyun Jung	373, 457	Manyalich, Marti	272, 342
Kim, Hyung Sook	383, 388	Martin, Dominique E2	22, 260, 552, 666
Kim, Jong Hun	301	Matas, David	267
Kim, Kyung Ae	672	Matsuno, Naoto	620, 623
Kim, Mihyeong	361, 376	McEvoy, Leanne M	487
Kim, Minhwa	281	Mehakovic, Eva	293, 496
Kim, Myoung Soo	331	Menjivar, Ana Teresa T	436, 684
Kim, Ok Kyung	378	Moench, Kerstin	251
Kim, Sang II	101, 252	Mone, Thomas D	531
Kim, Song-Yi	624	Mongkolchai, Sasipin	451
Kim, Soon-II	520	Morel, Philippe	700, 733
Kim, Suejin	370	Murphy, Paul	271, 437, 562
Kirste, Günter	102, 522, 702	Na, Sungwon	402
Koo, Jenny	543	Najafizadeh, Katayoun	463
Kumar, Pallavi	559	Nakagawa, Thomas	211, 412
Kusaka, Mamoru	351	Naqvi, S.A. Anwar	603, 691
Larson, Susan Mau	530, 712	Nathan, Howard M120, 3	58, 420, 495, 722
Lee, Dong-Gyu	576	Niles, Patricia A	460
Lee, Hwajung	453	Northam, Holly L	292
Lee, Jae Geun	513, 685	Novitzky, Dimitri O	411
Lee, Jae Yeon	572, 573, 574	O'Connor, Kevin	703
Lee, Jeong Lim	482	O'Meeghan, Rosemary A	354, 430, 455
Lee, Myounghwa	462	Obara, Hiromichi	625
Lee, Po-Chang	541	Ogawa RN, Mayuko	571
Lee, Saerom	561	Oh, Dong Kyu	355, 646
Lee, Suk-Koo	132	Oh, Jaesook	465

PRESENTER INDEX

Oh, Joo Youn	121
Olofsson Storrø, Monika	456
Opdam, Helen I	401, 503
Orlowski, Jeffrey P	431, 502
Ostrowski, Marek	265, 303
Park, Chung-Gyu	323
Park, Hojong	305
Park, Hyunjin	294
Park, Myoung Hee	501
Park, Sang Jun	488, 566
Patrzalek, Dariusz J	212
Pilcher, David V	357, 434
Pirenne, Jacques	240
Pleass, Henry C	309
Pruett, Timothy L	343
Punch, Jeffrey D	452
Rahman, Mir M	268, 504, 689
Ralph, Angelique F	636, 683
Reznik, Oleg N	628
Rogers, Meg M	701
Rojas-Pena, Alvaro	270
Rudich, Steven M	259, 310, 641
Sandal, Shaifali	621
Sarlo, Rodrigo Al	633
Sasaki, Hitomi	353
Scandling, John D	320
Schachtner, Thomas	615, 618
Schneeberger, Stefan	232, 333
Segev, Dorry L	341, 601
Seth, Avnish K	446, 613
Shafaghi, Shadi	507, 508, 626
Shaheen, Faissal A.M364, 56	64 (see page 39),
	647, 723
Shahrestani, Sara	515
Sheiman, Avivit A	
Shingu, Miho	389
Shinozaki, Naoshi	540

Shroff, Sunil544, 660
Siemionow, Maria230
Silva, Isaac A283
Simon, Andre112, 242, 243, 330
Skwirczyńska-Szalbierz, Edyta285, 575
Solek Pastuszka, Joanna284
Son, Sunyoung363, 550
Song, Sanghee676, 677
Sora, Cha551
Stegall, Mark D. D322
Strempel, Mari Maesc622
Suh, Kyung-Suk386, 681
Surendra, Naren Kumar432
Swe, Htar Kyi694
Tanabe, Kazunari523
Tong, Allison600
Traino, Heather M454, 497, 498
Trompeta, Joyce A385, 682
Tullius, Stefan G110, 241
Uryuhara, Yoko467
Waisaya, Jidapha560
White, Vanessa M290, 448
Woodside, Kenneth J350
Yandle, Kathy P440, 442, 518
Yeong, Youngsoon494
Yoo, James J470
Yoo, Kyung Don367, 648
Yoshikai, Shun-ichi667
Yoshikawa, Mikiko491
Young, Kimberly P130, 202, 312, 711, 732
Ysebaert, Dirk K.V223
Yu, Jinsook555, 556
Yuan, Xiaopeng674
Yun, Ohhyuk280

